https://trial.medpath.com/news/b34a7ee66671f442/immunitas-therapeutics-unveils-promising-preclinical-data-for-first-in-class-anti-cd161-antibody-imt-380-in-autoimmune-diseases 2025-07-31T21:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/5dbed20d6817f310/duo-trial-reveals-promise-for-durvalumab-olaparib-combination-in-early-stage-endometrial-cancer 2025-07-31T21:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/f93b2369e568e7a6/phase-2-alzheimer-s-trial-reveals-significant-racial-disparities-in-patient-screening-for-tau-targeting-therapy 2025-07-31T21:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/6c1d4bcc04e3e698/frazier-healthcare-partners-closes-1-3-billion-fund-for-early-stage-biotech-investments 2025-07-31T21:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/01bec89920a962d0/altasciences-partners-with-voxcell-bioinnovation-to-integrate-3d-bioprinting-technology-into-preclinical-drug-development 2025-07-31T21:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/b3b68977321dd133/oncodesign-precision-medicine-advances-opm-101-melanoma-trial-amid-financial-restructuring 2025-07-31T21:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/e448ad8b4ff1dc1d/protopia-ai-secures-1-25m-air-force-contract-to-advance-privacy-preserving-ai-technology-for-secure-code-development 2025-07-31T21:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/48d30c462ec9a9a8/moonlake-immunotherapeutics-advances-sonelokimab-through-phase-3-trials-for-multiple-inflammatory-conditions 2025-07-31T21:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/84dffbf6214cb1f5/university-of-colorado-launches-29-million-effect-trial-to-evaluate-early-fibrinogen-replacement-in-trauma-care 2025-07-31T21:30:22+00:00 hourly 0.9 https://trial.medpath.com/news/8638abb0be838816/lantern-pharma-completes-japanese-enrollment-for-phase-2-harmonic-trial-testing-lp-300-in-never-smoker-lung-cancer-patients 2025-07-31T17:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/b83dc9f1a7a46978/immuneonco-s-cd47xcd20-bispecific-imm0306-advances-to-phase-ii-with-promising-efficacy-in-b-cell-lymphomas 2025-07-31T17:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/abebf8bbbd1809e1/marengo-therapeutics-strengthens-leadership-with-pfizer-veteran-dolsten-and-oncology-expert-tabernero 2025-07-31T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/785e9d3d543da682/medicenna-secures-five-new-patents-for-il-2-and-il-4-superkine-immunotherapies 2025-07-31T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/d01d8d2f912f4067/moderna-announces-10-workforce-reduction-as-part-of-1-5-billion-cost-cutting-initiative 2025-07-31T17:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/02490bc6ad9cbe80/chipscreen-biosciences-receives-fda-ind-approval-for-brain-penetrant-aurora-b-inhibitor-cs231295 2025-07-31T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/46a6033c70370f13/vanda-pharmaceuticals-reports-strong-q2-2025-results-with-multiple-drug-applications-under-fda-review 2025-07-31T17:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/020ba16cbe68377f/symbiosis-pharmaceutical-services-achieves-manufacturing-milestone-with-1000th-sterile-injectable-batch 2025-07-31T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/296259ff8754c706/ryvu-therapeutics-discovers-synergistic-mtor-akt-inhibitor-combination-for-colorectal-cancer-treatment 2025-07-31T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/bc8a4ef67416dfb8/abbvie-s-rinvoq-achieves-breakthrough-results-in-alopecia-areata-phase-iii-trial 2025-07-31T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/ac9a8970bb3714dc/fda-approves-expanded-biktarvy-indication-for-hiv-treatment-experienced-patients-restarting-therapy 2025-07-31T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/c92ef0860149497e/psyence-biomed-partner-psylabs-achieves-gmp-grade-ibogaine-production-milestone 2025-07-31T17:26:11+00:00 hourly 0.9 https://trial.medpath.com/news/8e6a09a692cabe32/china-establishes-initial-pricing-mechanism-for-new-drugs-to-boost-innovation-returns 2025-07-31T17:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/c3487dc8db0d9fd6/fda-approves-first-neuroimmune-modulation-device-for-rheumatoid-arthritis-treatment 2025-07-31T17:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/7f247b3d9e54a008/uk-cdmo-eramol-advances-sterile-manufacturing-facility-for-2026-launch 2025-07-31T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/9db84325d361b724/soligenix-s-sgx945-matches-efficacy-of-fda-approved-therapy-in-behcet-s-disease-phase-2a-trial 2025-07-31T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/967de611fc3ebbab/tirzepatide-demonstrates-cardiovascular-benefits-in-type-2-diabetes-patients-with-ascvd-and-osa 2025-07-31T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/91e45791b43e7df6/ultromics-secures-55m-series-c-to-scale-ai-powered-heart-failure-diagnostics-across-us-hospitals 2025-07-31T14:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/93734bde6952c31b/cdsco-rejects-zydus-phase-iii-clinical-trial-waiver-for-voclosporin-in-lupus-nephritis-treatment 2025-07-31T13:49:53+00:00 hourly 0.9 https://trial.medpath.com/news/e0d9910773ebfc6f/vertex-pharmaceuticals-faces-setbacks-in-pain-medicine-development-program 2025-07-31T13:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/84e35c19c40f8302/new-market-report-reveals-global-mycosis-fungoides-clinical-trial-landscape-with-major-pharma-players 2025-07-31T13:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/1e3697053c2eb8d5/aerorx-therapeutics-reports-positive-phase-2a-results-for-first-nebulized-laba-lama-combination-therapy-aero-007-in-copd 2025-07-31T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/663f332e0ae42b16/major-pharmaceutical-companies-lead-global-renal-failure-clinical-trials-landscape-in-2025 2025-07-31T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/66e141924d5f5a1c/fresenius-medical-care-partners-with-azenta-to-advance-precision-kidney-disease-care-through-genomic-analysis 2025-07-31T13:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/28d07ce1bb2a528e/world-s-first-vaccine-adjuvant-library-launches-to-accelerate-pandemic-preparedness 2025-07-31T13:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/42d055a2ed5ead58/beone-medicines-receives-ema-prime-designation-for-btk-degrader-bgb-16673-in-waldenstrom-s-macroglobulinemia 2025-07-31T13:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/b11a649ede2340a5/flu-associated-brain-swelling-in-children-shows-27-mortality-rate-despite-aggressive-treatment 2025-07-31T10:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/ca702ae7be2e8e03/unlv-researchers-achieve-99-pancreas-specific-mrna-delivery-using-novel-endo-nanoparticle-platform 2025-07-31T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/5e8c66c08879b6b1/touchlight-launches-mbdna-platform-achieving-75-knock-in-rates-in-primary-human-t-cells 2025-07-31T05:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/e81798da9800b2f0/lung-cancer-experts-convene-to-address-clinical-uncertainties-in-rapidly-evolving-treatment-landscape 2025-07-31T03:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/0ce94d92024f4e6e/comprehensive-safety-management-strategies-transform-pi3k-inhibitor-treatment-delivery-in-metastatic-breast-cancer 2025-07-31T02:58:18+00:00 hourly 0.9 https://trial.medpath.com/news/2f2f7b30c01844ca/kidney-cancer-experts-develop-new-strategies-to-advance-clinical-trials-for-rare-subtypes 2025-07-31T02:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/f944aa849c111938/gilead-launches-patent-challenge-against-chinese-military-institute-over-remdesivir-at-unified-patent-court 2025-07-31T01:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/4bf02c04e156c437/abbvie-in-advanced-talks-to-acquire-mental-health-company-gilgamesh-pharmaceuticals-for-1-billion 2025-07-31T00:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/8d976f164f044189/osteosarcoma-market-poised-for-significant-growth-through-2034-as-novel-therapies-enter-pipeline 2025-07-31T00:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/45936298a007679a/inka-health-partners-with-onemednet-to-develop-ai-powered-external-control-arms-for-cancer-drug-development 2025-07-31T00:58:36+00:00 hourly 0.9 https://trial.medpath.com/news/e741ddb69b4c60ff/medicinova-secures-30-million-standby-equity-agreement-to-advance-neurological-and-fibrotic-disease-programs 2025-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/634c56620717692d/fda-approves-modeyso-as-first-treatment-for-recurrent-h3-k27m-mutant-diffuse-midline-glioma 2025-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b4c5b818907733cc/topcon-acquires-ai-powered-diabetic-retinopathy-screening-company-iris-to-expand-connected-care-platform 2025-07-30T21:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/3d40c9a8acade511/sensei-biotherapeutics-to-present-phase-1-data-on-novel-vista-targeting-cancer-therapy-at-esmo-2025 2025-07-30T21:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/98cdcb2a799174d4/teva-raises-uzedy-revenue-outlook-to-190-200m-as-medincell-s-olanzapine-injectable-advances-toward-fda-filing 2025-07-30T21:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/e2227d8eee0cedf5/abbvie-loses-patent-term-extension-battle-for-venclexta-cancer-drug-against-uspto 2025-07-30T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/58cdf11ca75419b3/amgen-settles-denosumab-biosimilar-patent-dispute-with-accord-biopharma 2025-07-30T21:30:09+00:00 hourly 0.9 https://trial.medpath.com/news/002c1393375007f1/alcon-unveils-next-generation-retinal-surgery-technologies-at-asrs-annual-meeting 2025-07-30T21:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/b7de546f3a75787e/ai-driven-drug-repurposing-identifies-four-fda-approved-medications-with-lipid-lowering-effects 2025-07-30T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/19bf9ecdae897fcb/astrazeneca-and-revna-biosciences-launch-targeted-egfr-therapy-for-lung-cancer-patients-in-ghana 2025-07-30T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/2369983c82a62c9e/experimental-celiac-drug-shows-promise-in-treating-children-with-post-covid-inflammatory-syndrome 2025-07-30T21:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/cc71f8e95923444d/briapro-files-patent-for-tilsrx-platform-targeting-multiple-cancer-types-with-novel-multivalent-immunotherapy 2025-07-30T17:45:44+00:00 hourly 0.9 https://trial.medpath.com/news/eccb4e641b66a0be/eumentis-therapeutics-receives-fda-clearance-for-phase-2-trial-of-novel-pde10a-inhibitor-em-221-in-schizophrenia 2025-07-30T17:43:57+00:00 hourly 0.9 https://trial.medpath.com/news/47fa0e5e2eea7830/actio-biosciences-receives-fda-clearance-and-fast-track-designation-for-first-in-class-kcnt1-epilepsy-treatment 2025-07-30T17:43:31+00:00 hourly 0.9 https://trial.medpath.com/news/f3d51d0cbb2b911d/german-federal-patent-court-revokes-key-xarelto-patent-opening-door-for-generic-competition 2025-07-30T17:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/23e51a666c27bf46/aldevron-establishes-innovation-center-in-boston-biotech-hub-to-accelerate-genomic-medicine-development 2025-07-30T17:41:58+00:00 hourly 0.9 https://trial.medpath.com/news/40b030e7a5bbb08b/protagenic-therapeutics-secures-japanese-patent-for-modified-stilbenoid-epilepsy-treatment-through-2041 2025-07-30T17:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/3c4aac512c206d01/zuma-7-trial-demonstrates-survival-advantage-for-second-line-car-t-therapy-in-refractory-dlbcl 2025-07-30T17:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/f6f6a56f3714a7e4/cancer-immunotherapies-linked-to-increased-risk-of-liver-cholestasis-global-study-reveals 2025-07-30T17:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/2ed24aa47a9ee933/gsk-s-tim-3-inhibitor-cobolimab-fails-phase-iii-trial-in-advanced-lung-cancer 2025-07-30T17:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/a8d2eecf321cebb6/vyne-therapeutics-repibresib-gel-fails-to-meet-primary-endpoints-in-phase-2b-vitiligo-trial 2025-07-30T17:39:58+00:00 hourly 0.9 https://trial.medpath.com/news/d570f0c201b26e05/magentiq-eye-secures-series-a-funding-to-advance-ai-powered-colonoscopy-technology 2025-07-30T17:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/b31ead5a6defd57c/world-first-gene-therapy-restores-vision-in-patient-with-usher-syndrome-type-1b 2025-07-30T17:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/9f1b60403dda376b/nautilus-biotechnology-partners-with-allen-institute-to-advance-alzheimer-s-research-through-single-molecule-proteomics 2025-07-30T17:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/dfcbb552dc9a2f76/ionis-pharmaceuticals-reports-strong-q2-2025-results-raises-guidance-on-tryngolza-success 2025-07-30T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/ba5f79332ae7bfb4/cardiosense-receives-fda-clearance-for-cardiotag-first-wearable-to-monitor-heart-rhythm-and-mechanical-function 2025-07-30T17:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/6fdfd659da485163/emerald-clinical-trials-appoints-glenn-kerkhof-as-interim-ceo-following-leadership-transition 2025-07-30T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/d6c44190dec3cc71/fda-grants-orphan-drug-designation-to-vt3989-for-mesothelioma-treatment 2025-07-30T17:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/520470493db116e5/bioduro-and-atombeat-launch-ai-powered-platform-to-accelerate-peptide-drug-discovery 2025-07-30T17:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/edf65ba0fad38cc6/prisma-health-and-siemens-healthineers-expand-50m-partnership-to-advance-ai-driven-cancer-care 2025-07-30T13:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/06e753a7161c1ee6/dx-vx-secures-220-million-mrna-cancer-vaccine-licensing-deal-with-u-s-biotech-partner 2025-07-30T13:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/589c6af2e6f5d859/briacell-secures-new-zealand-patent-for-hla-matched-whole-cell-cancer-immunotherapy-technology 2025-07-30T13:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/b6ea5aea677fd769/anika-s-hyalofast-cartilage-repair-treatment-shows-mixed-results-in-phase-iii-trial 2025-07-30T13:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/84c24cfc1a07d18c/avacta-to-present-updated-phase-1a-data-for-fap-targeted-doxorubicin-conjugate-ava6000-at-esmo-2025 2025-07-30T13:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/4ef6649ed6a98b13/viridian-therapeutics-secures-385-million-deal-with-kissei-for-thyroid-eye-disease-therapies-in-japan 2025-07-30T13:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/2d0c80a0765322df/evotec-sells-toulouse-biologics-facility-to-sandoz-for-300m-in-strategic-asset-light-transition 2025-07-30T13:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/fe5b55043dbb8d96/genetic-analysis-launches-ga-map-mhi-guthealth-diagnostic-kit-for-recurrent-c-difficile-infection 2025-07-30T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/7fd2a06632ae4a32/bioventus-secures-fda-clearance-for-two-next-generation-peripheral-nerve-stimulation-devices 2025-07-30T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/18e4ec4684cbae2f/major-pharma-companies-establish-innovation-hubs-in-hyderabad-to-accelerate-drug-development 2025-07-30T09:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/5d47f1ebdb4090f7/nuoyuan-medical-s-pemefolacianine-completes-phase-i-trial-advances-precision-tumor-surgery 2025-07-30T09:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/a916aa0e9a5cdf65/italy-approves-first-gene-therapy-for-hemophilia-b-expanding-access-to-22-new-treatments 2025-07-30T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/c2c69727f6b377f9/sanofi-s-sar446523-receives-fda-orphan-drug-designation-for-relapsed-refractory-multiple-myeloma 2025-07-30T09:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/8a9adf2ca019ef3b/mission-barns-secures-first-usda-approval-for-cultivated-pork-fat-launches-commercial-products 2025-07-30T09:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/713eb39d02396180/esc-congress-2025-to-showcase-pivotal-cardiovascular-trials-with-global-health-impact 2025-07-30T09:27:18+00:00 hourly 0.9 https://trial.medpath.com/news/abc03619402d5848/china-launches-major-trial-testing-nafamostat-mesilate-for-sepsis-treatment-across-32-hospitals 2025-07-30T09:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/ce762d749da1bb57/esmo-2025-to-showcase-breakthrough-immunotherapy-trials-in-head-and-neck-and-endocrine-cancers 2025-07-30T09:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/4fe4f4449bfd6223/bd-receives-fda-510-k-clearance-for-rapid-point-of-care-covid-19-test 2025-07-30T06:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/d82b50edfd7def05/harbour-biomed-to-present-phase-ii-data-on-novel-anti-ctla-4-antibody-combination-for-treatment-resistant-colorectal-cancer-at-esmo-2025 2025-07-30T05:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/252d09f75481257e/md-anderson-partners-with-toppan-holdings-to-develop-organoid-based-personalized-cancer-treatment-platform 2025-07-30T05:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/bc3a0df22fdccb38/fda-official-dr-vinay-prasad-resigns-after-three-months-amid-sarepta-gene-therapy-controversy 2025-07-30T05:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/b34c3dd3a009c50a/ivonescimab-shows-promise-as-dual-vegf-pd-1-inhibitor-in-clear-cell-renal-cell-carcinoma 2025-07-30T05:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/c24d4af07495884f/cellipont-bioservices-expands-partnership-with-cellvax-for-personalized-gi-cancer-immunotherapy-manufacturing 2025-07-30T01:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/1d1b8f7baf17514e/leo-cancer-care-s-marie-r-receives-fda-510-k-clearance-for-revolutionary-upright-particle-therapy-platform 2025-07-30T01:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/62c000e765d09635/kyowa-kirin-to-present-phase-3-rocatinlimab-results-for-atopic-dermatitis-at-eadv-2025 2025-07-30T01:29:59+00:00 hourly 0.9 https://trial.medpath.com/news/0999021bae75fae1/blood-based-assay-detects-immunotherapy-response-up-to-5-months-earlier-than-standard-imaging 2025-07-30T01:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/492a175f8068055f/3d-printed-catheters-enable-direct-tumor-drug-delivery-for-liver-cancer-treatment 2025-07-30T01:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/67f4f5ea6bc011a9/diorasis-therapeutics-partners-with-northway-biotech-to-advance-aav-gene-therapy-for-open-angle-glaucoma 2025-07-30T01:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/a395f6b7fb92d8cc/sharp-therapeutics-advances-gaucher-disease-therapy-901-toward-clinical-trials-with-rho-partnership 2025-07-30T01:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/a220345777b21bb8/nota-ai-receives-fast-track-kosdaq-approval-for-ai-optimization-technology-ipo 2025-07-30T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/725fe825b76ea042/fda-grants-orphan-drug-designation-to-coagadex-for-rare-bleeding-disorder-associated-with-al-amyloidosis 2025-07-30T01:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/034cd8ced2a9b6c6/bionexus-gene-lab-and-fidelion-diagnostics-form-strategic-alliance-to-commercialize-revolutionary-liquid-biopsy-technology-in-southeast-asia 2025-07-30T01:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/6af91bb1a6b16d52/mitochondrial-transplantation-doubles-cisplatin-efficacy-in-advanced-lung-cancer-treatment 2025-07-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b08010f2d2390f2/nice-recommends-vanzacaftor-tezacaftor-deutivacaftor-for-cystic-fibrosis-treatment-in-england 2025-07-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/71c1dae79312b790/adc-safety-management-in-mtnbc-genetic-screening-and-prophylactic-strategies-emerge-for-sacituzumab-govitecan 2025-07-29T21:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/16c7a4f308ac20f9/ascellahealth-and-abeona-therapeutics-launch-comprehensive-support-program-for-zevaskyn-gene-therapy 2025-07-29T21:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/bdf6fa25efea6530/ltz-therapeutics-partners-with-eli-lilly-to-advance-first-in-class-myeloid-engager-platform 2025-07-29T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b6fb9a1ecc477f1/immunotherapy-alters-bone-marrow-environment-in-acute-myeloid-leukemia-study-reveals 2025-07-29T21:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/26bfa8672463d2ef/tme-pharma-implements-strategic-restructuring-to-advance-nox-a12-and-nox-e36-development 2025-07-29T21:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/8eaf752ed04fad29/ccr-researchers-develop-water-stable-chemical-warhead-to-enhance-cancer-drug-performance 2025-07-29T21:30:41+00:00 hourly 0.9 https://trial.medpath.com/news/6e5ca1195a1ef95c/therini-bio-initiates-phase-1b-trial-of-novel-anti-fibrin-antibody-thn391-for-alzheimer-s-disease 2025-07-29T21:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/882493a63b3b5507/gsk-advances-long-term-extension-study-of-gsk1070806-for-moderate-to-severe-atopic-dermatitis 2025-07-29T21:29:58+00:00 hourly 0.9 https://trial.medpath.com/news/fbeee18149f457f7/real-world-study-shows-comparable-effectiveness-of-four-monoclonal-antibodies-in-severe-asthma-treatment 2025-07-29T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/b93572e980739ce9/formation-bio-licenses-first-in-class-anti-cd226-monoclonal-antibody-for-autoimmune-diseases 2025-07-29T21:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/fb38888824fa4b24/ema-reviews-tecovirimat-following-clinical-trial-data-showing-lack-of-effectiveness-against-mpox 2025-07-29T21:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/8584961e597f807e/fda-establishes-new-regulatory-framework-for-uvc-disinfection-systems-in-healthcare 2025-07-29T21:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/bd9e52377a7f4372/bavarian-nordic-agrees-to-3-billion-take-private-deal-with-nordic-capital-and-permira 2025-07-29T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/c65bc2d7d8c93570/biotech-investment-downturn-creates-new-opportunities-as-select-vc-firms-raise-major-funds 2025-07-29T21:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/fbb668c6951d1ef6/crispr-edited-cish-knockout-til-therapy-shows-promise-in-metastatic-gastrointestinal-cancers 2025-07-29T21:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/e04d784d197c8cfa/maryland-drug-affordability-board-flags-two-diabetes-medications-as-cost-challenges 2025-07-29T17:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/df03673de2dc08c9/basilea-launches-phase-3-trial-for-novel-antifungal-fosmanogepix-in-invasive-mold-infections 2025-07-29T17:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/edcaf32cec32d912/rintatolimod-durvalumab-combination-shows-promise-in-metastatic-pancreatic-cancer-phase-2-trial 2025-07-29T17:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/554de4c9bd537b75/exonate-advances-exn407-eye-drop-to-phase-iib-trial-for-diabetic-retinopathy-treatment 2025-07-29T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/1b31344954869062/fulcrum-therapeutics-experimental-pill-shows-modest-increases-in-fetal-hemoglobin-for-sickle-cell-disease-treatment 2025-07-29T17:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/cbf476111abc2d8e/artbio-raises-132-million-series-b-to-advance-lead-212-radiopharmaceutical-for-prostate-cancer 2025-07-29T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/d679c305eff090c9/relief-therapeutics-to-merge-with-neurox-in-chf-1-billion-deal-creating-ai-driven-neurotherapeutics-platform 2025-07-29T17:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/a35fbb70bc66760d/ajax-therapeutics-and-schrodinger-expand-jak-inhibitor-partnership-with-new-target 2025-07-29T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/37608ffeaf261bdd/brain-inspired-supercomputer-deployed-at-leipzig-university-to-accelerate-ai-driven-drug-discovery 2025-07-29T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/7d793032f69418d6/ai-driven-drug-design-platform-achieves-70-success-rate-in-rorgt-inhibitor-discovery 2025-07-29T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/cc6626cf7fb7a29a/exozymes-achieves-breakthrough-in-nct-production-with-ai-driven-biomanufacturing-platform 2025-07-29T17:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/d3fe0b79207139b8/virocell-biologics-partners-with-avencell-therapeutics-to-advance-dual-targeted-allogeneic-car-t-therapy 2025-07-29T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/4304c94d849473cf/bausch-health-acquires-durect-for-63m-to-advance-breakthrough-alcoholic-hepatitis-treatment 2025-07-29T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/b937542af20b0f0d/centauri-therapeutics-secures-additional-5-1m-from-carb-x-to-advance-novel-antimicrobial-abx-01-to-clinical-trials 2025-07-29T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/d23f29c5c5d22f29/merck-announces-3-billion-cost-cutting-initiative-to-prepare-for-keytruda-patent-expiration 2025-07-29T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/1a70d20c8929fc8b/multibeam-raises-31-million-series-b-to-advance-e-beam-lithography-for-ai-chip-manufacturing 2025-07-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/51d03b728998a35d/arrowhead-pharmaceuticals-receives-100-million-milestone-payment-for-aro-dm1-myotonic-dystrophy-treatment 2025-07-29T09:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/bf048135ed6ffea8/celltrion-secures-preferred-bidder-status-for-us-manufacturing-facility-to-navigate-tariff-challenges 2025-07-29T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/34a2f544890e902e/td2-oncology-and-curadh-form-strategic-partnership-to-accelerate-radiopharmaceutical-development-for-solid-tumors 2025-07-29T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/05ccc94037b3b946/syntara-initiates-first-in-human-trial-of-topical-anti-fibrotic-drug-snt-9465-for-hypertrophic-scars 2025-07-29T05:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/f9a35b0c47764ec8/alphamab-oncology-s-her2-targeting-adc-jskn003-receives-fda-orphan-drug-designation-for-gastric-cancer 2025-07-29T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/b008033b17416c91/brazilian-research-institute-hcor-accelerates-phase-3-immunology-trials-with-oracle-clinical-platform 2025-07-29T05:25:57+00:00 hourly 0.9 https://trial.medpath.com/news/1c88431abf91d43c/virax-biolabs-strengthens-board-with-diagnostics-veteran-iain-miller-as-company-advances-immune-profiling-platform 2025-07-29T04:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/08b1ab4e7039c55f/fertility-preservation-gains-momentum-in-cancer-care-as-awareness-and-access-improve 2025-07-29T02:59:25+00:00 hourly 0.9 https://trial.medpath.com/news/3d6005dc57892623/immunotherapy-advances-in-sarcoma-treatment-targeting-the-tumor-microenvironment-and-cancer-testis-antigens 2025-07-29T02:58:02+00:00 hourly 0.9 https://trial.medpath.com/news/6893ae12aa45764a/personalized-deep-brain-stimulation-shows-promise-for-improving-walking-in-parkinson-s-disease 2025-07-29T01:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/6386799a8219c8ef/bristol-myers-squibb-and-bain-capital-launch-300m-immunology-drug-development-venture 2025-07-29T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/e4f73236714d8326/immvira-s-engineered-exosomes-for-hair-growth-and-fat-reduction-receive-inci-certification-opening-path-to-global-markets 2025-07-29T01:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/59e24933a2384684/nyxoah-s-genio-system-shows-strong-patient-satisfaction-and-efficacy-in-dream-pivotal-study-publication 2025-07-29T01:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/576afe4ee961d62b/torrent-pharmaceuticals-prepares-first-wave-semaglutide-launch-following-patent-expiry 2025-07-29T01:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/b095e50943163477/adaptimmune-sells-tecelra-and-cell-therapy-assets-to-us-worldmeds-for-85-million-amid-financial-crisis 2025-07-29T01:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/af5a710d3802b4b8/life-biosciences-partners-with-singapore-institute-to-advance-epigenetic-therapies-for-age-related-diseases 2025-07-29T01:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/ee389a112607d7ac/verabind-tau-assay-shows-superior-early-detection-capabilities-for-alzheimer-s-disease-in-aaic-2025-studies 2025-07-29T01:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/05714f742f5a6162/xvivo-heart-preservation-technology-faces-6-12-month-ce-approval-delay-despite-promising-clinical-results 2025-07-29T01:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/9728b5181fd2b891/asahi-kasei-to-build-fourth-planova-virus-filter-plant-in-japan-with-government-support 2025-07-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb47b4c4eec6b934/gen-pharmaceuticals-reports-positive-phase-1-results-for-novel-alzheimer-s-drug-sul-238 2025-07-28T21:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/b5db64fcddb9d03a/pluristyx-secures-strategic-investment-to-advance-ipsc-technologies-and-gene-edited-cell-lines 2025-07-28T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/033ef33db259d090/federal-court-rules-prep-act-cannot-shield-covid-test-swab-manufacturer-from-patent-infringement-claims 2025-07-28T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/c702ec43bb2c7384/global-alzheimer-s-platform-foundation-and-genentech-partner-to-enhance-diversity-in-alzheimer-s-clinical-trials 2025-07-28T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/dbbfbd57256daf8c/can-fite-biopharma-raises-5-million-in-public-offering-to-fund-cancer-and-inflammatory-disease-drug-development 2025-07-28T21:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/d6235bd0b754ae8a/qualigen-therapeutics-secures-4-5-million-in-series-a-3-preferred-stock-financing-to-advance-cancer-therapeutics-pipeline 2025-07-28T21:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/5a15e461aa9c72c5/u-s-pointer-study-demonstrates-structured-lifestyle-interventions-significantly-improve-cognitive-function-in-at-risk-older-adults 2025-07-28T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/654a2da929669658/avacta-completes-transition-to-pure-play-therapeutics-with-ps2-2m-coris-sale 2025-07-28T17:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/963e07e8a7187615/oncoc4-s-onc-841-shows-promise-as-first-in-class-alzheimer-s-disease-immunotherapy-in-preclinical-studies 2025-07-28T17:39:27+00:00 hourly 0.9 https://trial.medpath.com/news/d241cd6a2813ce39/zetagen-therapeutics-secures-uspto-patents-for-novel-intratumoral-breast-cancer-platform 2025-07-28T17:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/3304479707df599e/cumulus-neuroscience-validates-at-home-digital-biomarkers-show-greater-sensitivity-than-standard-alzheimer-s-assessment-scale 2025-07-28T17:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/8e5af3c871a7f39c/isobio-secures-5-million-series-seed-funding-to-advance-antibody-isotope-conjugates-for-cancer-treatment 2025-07-28T17:36:34+00:00 hourly 0.9 https://trial.medpath.com/news/82cc0f45e7f35981/fda-issues-warning-letter-to-glenmark-pharmaceuticals-following-manufacturing-quality-violations 2025-07-28T17:35:47+00:00 hourly 0.9 https://trial.medpath.com/news/e3fb023685bb0c93/aim-immunotech-reports-promising-mid-year-results-from-phase-2-pancreatic-cancer-combination-therapy-study 2025-07-28T17:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/727c28338b6841f9/cancer-drug-sb431542-shows-triple-action-antiviral-efficacy-against-covid-19-in-preclinical-studies 2025-07-28T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/7a5a10f760113187/acclaim-trial-completes-enrollment-eight-months-ahead-of-schedule-for-colorectal-liver-metastases-study 2025-07-28T17:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/85221db580ff2c99/angiodynamics-launches-ambition-btk-trial-for-critical-limb-ischemia-treatment-using-auryon-laser-technology 2025-07-28T17:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/7829752c1e0fc605/abelacimab-shows-low-bleeding-rates-in-phase-2-periprocedural-trial-may-simplify-anticoagulation-management 2025-07-28T17:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/755b25cc891d38ca/renovorx-launches-multi-center-panther-registry-study-to-evaluate-real-world-safety-of-renovocath-device 2025-07-28T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/dbafaf6bcbb39962/filgotinib-meets-primary-endpoint-in-phase-3-trial-for-axial-spondyloarthritis 2025-07-28T13:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/b6bdf332e9329dd7/china-medical-system-secures-nmpa-acceptance-for-zunvyl-alzheimer-s-drug-application 2025-07-28T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/baa16f628ed968e4/fda-accepts-bone-mineral-density-as-primary-endpoint-for-entera-bio-s-oral-osteoporosis-drug-phase-3-trial 2025-07-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/51abee3c3391b20b/onconic-therapeutics-advances-nesuparib-to-phase-2-trials-for-pancreatic-cancer-treatment 2025-07-28T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/b9876d94bab45dab/arrowhead-pharmaceuticals-weathers-sarepta-partnership-turbulence-as-11-billion-rnai-deal-faces-market-scrutiny 2025-07-28T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/55740c34b6cdf4e6/gsk-secures-12-billion-partnership-with-hengrui-for-12-drug-development-portfolio 2025-07-28T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/465043c11d54e5f5/boehringer-ingelheim-partners-with-re-vana-for-1b-extended-release-eye-therapy-development 2025-07-28T13:30:29+00:00 hourly 0.9 https://trial.medpath.com/news/1f220298d4c8455b/ucla-study-shows-can-fite-s-piclidenoson-restores-function-in-vascular-dementia-model 2025-07-28T13:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/ced5515c20e7353d/zilbrysq-market-projected-to-grow-21-64-annually-through-2030-following-fda-approval-for-myasthenia-gravis 2025-07-28T13:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/ab6220ba077259de/quanterix-launches-first-to-market-p-tau-205-and-p-tau-212-assays-for-alzheimer-s-disease-research 2025-07-28T13:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/cd12eff1289e3839/zymeworks-receives-fda-clearance-for-zw251-novel-glypican-3-targeted-adc-for-hepatocellular-carcinoma 2025-07-28T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/30942d4e0fe2d973/artcline-reaches-100-patient-milestone-in-septic-shock-immune-cell-therapy-trial 2025-07-28T13:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/54b2e38818dee594/diverse-biotech-secures-patents-for-novel-antibody-cannabinoid-and-antibiotic-cannabinoid-conjugates 2025-07-28T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d605b52708d5e395/transgene-and-bioinvent-to-present-updated-bt-001-oncolytic-virus-data-at-esmo-2025 2025-07-28T09:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/8ded5abacfed46df/ivonescimab-demonstrates-superior-efficacy-in-phase-iii-lung-cancer-trials-positioning-for-global-regulatory-approvals 2025-07-28T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/4ef54931e0b668ff/kyan-technologies-ex-vivo-platform-demonstrates-clinical-utility-in-relapsed-refractory-non-hodgkin-lymphoma 2025-07-28T09:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/8a52ea144d001d29/robles-bioceutics-partners-with-innovigen-to-scale-production-of-senolytic-enhanced-skincare 2025-07-28T08:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/9fe1417bffd70eea/delhi-high-court-rules-against-roche-in-pertuzumab-patent-disclosure-case-clarifies-section-104a-requirements-for-biologics 2025-07-28T05:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/c2efb808b9de1fa6/indian-drug-regulator-orders-enhanced-ndma-monitoring-for-ranitidine-amid-cancer-concerns 2025-07-28T05:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/05d7f81b545a5bcf/gsk-secures-12-5-billion-deal-with-hengrui-for-copd-drug-and-11-additional-programs 2025-07-28T05:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/95e3f4b5a82c115c/china-approves-xpovio-for-second-line-multiple-myeloma-treatment-based-on-phase-iii-bench-trial 2025-07-28T05:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/cb792cca0cbc0b1a/osr-holdings-acquires-korean-non-invasive-glucose-monitoring-pioneer-woori-io 2025-07-28T00:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/a9f848e683850043/cuhk-develops-magnetic-microcatheter-for-precise-treatment-of-acute-ischemic-stroke 2025-07-28T00:57:47+00:00 hourly 0.9 https://trial.medpath.com/news/86eb7e005d82900e/roche-launches-clinical-trial-for-trontinemab-to-prevent-alzheimer-s-disease 2025-07-27T21:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/97e7d082607fcd99/combination-cardiovascular-therapies-show-promise-in-slowing-cognitive-decline-and-reducing-dementia-pathology 2025-07-27T21:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/afbd738e1aa0df07/immunoact-achieves-profitability-with-india-s-first-car-t-therapy-treating-over-350-cancer-patients 2025-07-27T21:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/dbb276e6136dd514/colorcon-opens-state-of-the-art-film-coating-manufacturing-facility-in-malaysia-to-strengthen-asia-pacific-supply-chain 2025-07-27T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/04decccf17db64ce/granules-india-ceo-dr-k-v-sitaram-rao-announces-resignation-effective-july-2025 2025-07-27T17:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/fc6bf3f6668c34d4/caspofungin-trough-concentrations-above-3-58-mg-ml-linked-to-improved-clinical-outcomes-in-retrospective-study 2025-07-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/84fe193b049afa54/rigicon-initiates-ausome-study-for-artificial-urinary-sphincter-fda-approval 2025-07-27T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/ee1a0b69e7b10aff/fecal-microbiota-transplantation-shows-safety-and-tolerability-in-six-month-parkinson-s-disease-pilot-study 2025-07-27T09:23:23+00:00 hourly 0.9 https://trial.medpath.com/news/f7b7b3e06211c286/bangladesh-pharmaceutical-companies-risk-losing-royalty-free-access-to-15-biologic-drugs-due-to-regulatory-delays 2025-07-27T01:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/50bae8a6d090ce93/india-maintains-firm-stance-against-patent-evergreening-in-global-trade-negotiations 2025-07-27T01:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/c45a701879831a6f/novel-therapeutic-strategies-show-promise-for-overcoming-immunotherapy-resistant-nsclc 2025-07-27T01:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/0d1d892077df31bc/nice-expands-nhs-funding-for-astrazeneca-s-lokelma-to-include-outpatient-care 2025-07-27T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/4208f2c22b7b73c7/nppa-committee-identifies-patent-discrepancies-in-intas-clozapine-er-pricing-application 2025-07-26T21:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/31fd01ace086d32d/applied-dna-sciences-secures-600000-follow-on-order-for-cancer-diagnostic-component 2025-07-26T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/7ba6eb8330ff6898/ptab-director-denies-amgen-s-ipr-challenges-against-bristol-myers-squibb-s-opdivo-patents-based-on-settled-expectations 2025-07-26T17:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/c4c644b81ed92881/cytodyn-files-100m-mixed-shelf-offering-to-advance-leronlimab-through-phase-iii-trials 2025-07-26T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/5a1bb1b5445160ef/indoco-remedies-receives-eu-gmp-certification-for-sterile-manufacturing-facility-in-goa 2025-07-26T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/6fea3094c8aefb9a/menopausal-hormone-therapy-shows-persistent-bone-protection-despite-temporary-risk-increase-after-discontinuation 2025-07-26T17:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/be67656e97d2d997/io-biotech-s-cylembio-cancer-vaccine-misses-primary-endpoint-in-phase-3-melanoma-trial 2025-07-26T14:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/585691d266b19385/ghana-receives-africa-s-first-novaseq-x-plus-sequencer-to-address-cancer-care-disparities 2025-07-26T13:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/8ffc2f5e1384adc1/medicare-part-b-drug-price-negotiations-may-restrict-patient-access-to-cancer-and-autoimmune-treatments 2025-07-26T09:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/c1d9786d332d34b8/ut-sanofi-partnership-develops-ai-model-to-accelerate-mrna-therapeutic-discovery 2025-07-26T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/939c0426428d8adc/biogen-s-zurzuvae-receives-ema-panel-recommendation-for-postpartum-depression-treatment 2025-07-26T09:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/1a079a31053687d6/community-oncologist-highlights-persistent-access-barriers-to-targeted-breast-cancer-therapies 2025-07-26T09:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/6b390ba96df20a15/novel-dental-floss-based-vaccine-delivery-system-shows-promise-against-influenza-in-preclinical-study 2025-07-26T05:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/d1228ed7acce45c2/delhi-high-court-rejects-roche-s-bid-to-force-zydus-to-disclose-sigrima-manufacturing-process 2025-07-26T05:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/527c698e52288aa1/sen-jam-pharmaceutical-initiates-phase-2-trial-for-first-in-class-hangover-prevention-therapy-sjp-001 2025-07-26T05:23:22+00:00 hourly 0.9 https://trial.medpath.com/news/8761d64ab1ec3b09/health-canada-approves-clearside-biomedical-s-xipere-for-uveitic-macular-edema-treatment 2025-07-26T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/5b94f89d28f69fde/omeros-raises-22-million-in-direct-offering-to-fund-narsoplimab-development-amid-regulatory-review 2025-07-26T05:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/afbe5e1202488cf3/uva-launches-first-of-its-kind-psilocybin-trial-for-prolonged-grief-disorder 2025-07-26T05:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/aabdab8571e182a0/multidisciplinary-approach-and-technology-integration-show-promise-for-addressing-hidradenitis-suppurativa-care-disparities 2025-07-26T05:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/43e8638038284b8a/agenus-advances-bot-bal-combination-therapy-with-phase-3-battman-trial-launch-for-metastatic-colorectal-cancer 2025-07-26T05:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/c5e0c343e4a1abeb/new-jersey-senator-advocates-for-state-led-healthcare-ai-implementation-and-rural-health-investment 2025-07-26T05:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/d19bceecdcec5955/france-prepares-major-drug-pricing-reforms-as-ceps-report-due-july-2025 2025-07-26T02:57:38+00:00 hourly 0.9 https://trial.medpath.com/news/30ace1354e0652fa/comprehensive-genomic-profiling-shows-cost-neutrality-despite-underutilization-in-advanced-cancer-care 2025-07-26T02:57:25+00:00 hourly 0.9 https://trial.medpath.com/news/cd91b3da5bebccb4/early-onset-gastrointestinal-cancers-surge-globally-rising-faster-than-any-other-cancer-type-in-young-adults 2025-07-26T02:57:13+00:00 hourly 0.9 https://trial.medpath.com/news/2ed2848614a50f68/atai-life-sciences-schizophrenia-cognitive-drug-inidascamine-fails-primary-endpoint-in-phase-2-trial 2025-07-26T01:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/721ac8cd307518cb/fda-upgrades-recall-of-160000-bottles-of-levothyroxine-due-to-subpotent-active-ingredients 2025-07-26T01:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/e97574541587ab15/glp-1-receptor-agonists-show-promise-for-pcos-treatment-in-early-studies 2025-07-26T01:01:06+00:00 hourly 0.9 https://trial.medpath.com/news/23e5d533a7aedd2a/recognify-s-inidascamine-misses-primary-endpoint-in-phase-2b-trial-for-schizophrenia-associated-cognitive-impairment 2025-07-26T00:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/083e6c9e6f1f8c6e/ema-recommends-approval-of-aqneursa-for-niemann-pick-type-c-disease-treatment 2025-07-26T00:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/db73d94ed2bbde3e/european-commission-approves-cabometyx-for-advanced-pancreatic-neuroendocrine-tumors 2025-07-26T00:58:19+00:00 hourly 0.9 https://trial.medpath.com/news/ceb996f3c2eff3eb/centanafadine-shows-promise-for-pediatric-and-adolescent-adhd-in-phase-3-trials 2025-07-25T21:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/1d0ed01ce3d2c4b5/seca-trial-challenges-routine-aspirin-cessation-in-chronic-subdural-hematoma-surgery 2025-07-25T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/80974cddbfcdbad1/insmed-opens-cambridge-r-d-facility-focused-on-synthetic-rescue-platform-for-rare-diseases 2025-07-25T21:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/afac68f669d0dccd/comprehensive-pipeline-analysis-reveals-200-investigational-drugs-for-metastatic-hormone-refractory-prostate-cancer 2025-07-25T21:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/84d438d1c6cdb1e7/naip-breaks-ground-on-state-of-the-art-pharmaceutical-research-centre-in-nigeria-s-anambra-state 2025-07-25T21:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/bff5c8d1e86dc5e5/cilcare-secures-eur50000-grant-for-3d-bioprinted-human-model-to-advance-hearing-loss-drug-development 2025-07-25T21:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/d484f7cea3597de7/leveragen-and-propeller-bio-form-strategic-partnership-to-advance-next-generation-antibody-discovery-platform 2025-07-25T21:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/2b0c068b7d239fc0/multiple-cancer-clinical-trials-advance-with-remote-study-models-and-novel-therapeutics 2025-07-25T21:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/f63588c5f2cbbbde/glp-1-drugs-show-promise-for-asthma-control-in-obese-patients-beyond-weight-loss-benefits 2025-07-25T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/95d08b0de64cb174/phio-pharmaceuticals-secures-u-s-manufacturing-partnership-for-pd-1-silencing-cancer-therapy-ph-762 2025-07-25T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/6f15668db86a3a7f/india-uk-free-trade-agreement-raises-concerns-over-access-to-affordable-medicines 2025-07-25T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/af61ba978ce80abc/fda-complete-response-letters-highlight-growing-cmc-challenges-in-immunotherapy-development 2025-07-25T17:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/1c62e0e9d394f695/lyell-immunopharma-secures-100-million-private-placement-to-advance-car-t-cell-therapy-development 2025-07-25T17:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/b688d06ed65d0275/cannabis-use-disorder-pipeline-shows-promise-with-novel-therapies-in-development 2025-07-25T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/f96dcb2392cd4bf5/bristol-myers-squibb-appoints-astrazeneca-s-cristian-massacesi-as-new-chief-medical-officer 2025-07-25T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/531f1f5a3345d3f1/european-regulators-recommend-approval-of-vorasidenib-for-idh-mutant-grade-2-glioma 2025-07-25T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/a55f955014c16158/amgen-s-repatha-faces-safety-scrutiny-as-heroic-study-evaluates-cardiovascular-benefits 2025-07-25T17:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/f18271f2381557e3/aiims-led-study-demonstrates-equal-efficacy-of-three-two-drug-hypertension-combinations-in-south-asian-patients 2025-07-25T17:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/5a090ab43681e709/fda-approves-doptelet-for-pediatric-immune-thrombocytopenia-with-new-sprinkle-formulation 2025-07-25T17:23:31+00:00 hourly 0.9 https://trial.medpath.com/news/1c2f81a5983fb915/tirzepatide-shows-greater-benefits-in-higher-bmi-patients-with-heart-failure-and-obesity-summit-trial-analysis-reveals 2025-07-25T13:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/73d66eeace9a0848/believer-meats-becomes-first-foreign-company-to-secure-fda-clearance-for-cultivated-chicken 2025-07-25T13:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/99951c92e4147d94/kintor-pharma-s-kx-826-hair-loss-treatment-achieves-primary-endpoint-in-phase-ii-trial 2025-07-25T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/a00e236e7a0fd78f/plant-virus-nanoparticles-show-promise-as-novel-cancer-immunotherapy-in-preclinical-studies 2025-07-25T13:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/de2b9ecd9b5166c9/european-regulators-recommend-expanding-novo-nordisk-s-alhemo-for-hemophilia-a-and-b-without-inhibitors 2025-07-25T13:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/cf0ea6cde187cf86/milliporesigma-and-washington-university-strengthen-90-year-partnership-to-accelerate-life-sciences-innovation 2025-07-25T13:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/4307897baf7f4270/beone-medicines-expands-beijing-r-d-center-to-accelerate-oncology-drug-development 2025-07-25T13:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/8791526656781f30/adocia-s-ultra-rapid-insulin-biochaperone-lispro-meets-primary-endpoint-in-phase-3-trial-for-type-2-diabetes 2025-07-25T13:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/9cab7ed868c044e0/fermented-stevia-extract-shows-selective-cytotoxicity-against-pancreatic-cancer-cells-in-laboratory-study 2025-07-25T13:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/13c65f3d7eb3ae13/precirix-receives-fda-clearance-to-begin-phase-1-trial-of-cam-fap-ac-225-targeted-alpha-therapy 2025-07-25T13:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/a31a00bea67a23f1/sumitomo-corporation-partners-with-ai-startup-airato-to-revolutionize-cancer-radiation-therapy-planning 2025-07-25T13:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/ae1407dca39229a2/atrial-fibrillation-pipeline-shows-robust-development-with-15-novel-therapies-from-leading-pharmaceutical-companies 2025-07-25T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b8718bf74ad9db9/eu-regulatory-approval-advances-pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-for-2025-2026-season 2025-07-25T09:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/379b1f2436885108/everest-medicines-raises-hk-1-57-billion-to-accelerate-ai-mrna-platform-and-pipeline-development 2025-07-25T09:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/54a9c4d85b056098/ocugen-initiates-phase-2-3-gardian3-trial-for-stargardt-disease-gene-therapy 2025-07-25T05:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/5d784631cd6ba4f7/rocket-pharmaceuticals-cuts-30-of-workforce-refocuses-on-cardiovascular-gene-therapies 2025-07-25T05:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/02870ffa39b5a960/tga-investigates-15-fold-spike-in-vyvanse-adverse-event-reports-amid-social-media-influence 2025-07-25T05:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/b18ab33ed5230b1d/new-study-links-depo-provera-to-doubled-brain-tumor-risk-as-pfizer-faces-over-1200-lawsuits 2025-07-25T05:23:02+00:00 hourly 0.9 https://trial.medpath.com/news/9d616a9fe280484d/leads-biolabs-raises-189-million-in-hong-kong-ipo-advances-first-in-class-4-1bb-immunotherapy 2025-07-25T05:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/4eaabdbbf7afa321/absci-raises-50-million-to-advance-ai-driven-drug-discovery-platform-and-internal-pipeline 2025-07-25T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/221b93a66ddd78e0/epic-trial-shows-immunotherapy-extends-survival-in-advanced-penile-cancer-patients 2025-07-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/2faf6a6b0522b417/procept-biorobotics-expands-prostate-cancer-trial-to-outpatient-setting-with-first-asc-procedures 2025-07-25T01:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/0b7f087e060d262c/magnetically-steerable-drug-delivery-vesicles-show-promise-for-precision-cancer-treatment 2025-07-25T01:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/077d469df2d2f030/coya-therapeutics-coya-303-demonstrates-anti-inflammatory-effects-in-preclinical-alzheimer-s-model 2025-07-25T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/0a82ee41deed614c/janux-therapeutics-advances-multi-platform-pipeline-with-novel-arm-technology-for-autoimmune-diseases 2025-07-25T01:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/e56eaf14b3b9b2e4/nextcure-s-anti-siglec-15-antibody-nc605-shows-promise-for-osteogenesis-imperfecta-treatment-in-preclinical-study 2025-07-25T01:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/337c63b801409ce2/insmed-s-brensocatib-wins-fda-approval-as-first-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-07-25T01:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/b5ab5dedea4c2e78/pedal-study-demonstrates-prospera-kidney-test-accurately-predicts-long-term-outcomes-after-transplant-rejection 2025-07-25T01:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/386653f3a39f9e9e/hydroxychloroquine-shows-promise-for-kidney-protection-in-primary-glomerular-disease-and-lupus-nephritis 2025-07-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e919d51a71edacb/iran-israel-conflict-disrupts-global-clinical-trial-landscape-as-india-overtakes-iran-in-q2-2025 2025-07-24T21:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/447619510e93262b/stevanato-group-secures-eur200-million-financing-to-expand-biologics-manufacturing-capacity 2025-07-24T21:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/15cfd6a09839a712/novel-bispecific-antibody-xmab30819-shows-promise-in-advanced-clear-cell-renal-cell-carcinoma 2025-07-24T21:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/128d343d6983a75c/bayer-initiates-phase-clinical-trial-for-bay3018250-in-deep-vein-thrombosis-treatment 2025-07-24T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/ea9e71f4ff7b1c1b/biocardia-seeks-japan-pmda-approval-for-cardiamp-cell-therapy-in-heart-failure-treatment 2025-07-24T21:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/d88111d481a2a7a9/roche-discontinues-obesity-drug-ct-173-from-2-7b-carmot-acquisition-citing-lack-of-competitiveness 2025-07-24T21:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/2a41507dacfae091/gate-bioscience-partners-with-lilly-in-856-million-deal-to-develop-novel-molecular-gate-therapeutics 2025-07-24T21:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/af8ceddd1ce856c8/gnt-pharma-advances-first-in-class-dual-action-stroke-therapy-nelonemdaz-to-global-phase-3-trials 2025-07-24T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/42cdeb5982fa2cfe/cdx-diagnostics-receives-fda-breakthrough-device-designation-for-ai-powered-wats3d-esophageal-cancer-diagnostic-system 2025-07-24T21:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/5b6f686cf83474f8/tcg-labs-soleil-raises-400m-to-build-single-asset-biotech-startups-for-strategic-partnerships 2025-07-24T21:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/ce13a93976bf1fe7/medcomms-experts-acquires-nexgen-healthcare-communications-to-expand-global-medical-communications-platform 2025-07-24T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/bbeea2236f5bdd1f/celularity-s-pda-002-shows-promise-in-phase-2-trial-for-diabetic-foot-ulcers-with-peripheral-artery-disease 2025-07-24T17:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/47334586c04b5df0/krystal-biotech-s-kb304-gene-therapy-achieves-100-response-rate-in-phase-1-decollete-wrinkle-trial 2025-07-24T17:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/21702a6738fa6f66/ideaya-biosciences-to-present-phase-2-darovasertib-data-for-uveal-melanoma-at-esmo-2025 2025-07-24T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/73185afdfaa8d8a0/roche-explores-direct-to-consumer-drug-sales-model-to-reduce-us-patient-costs 2025-07-24T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/48ba7bb96bee15ec/clinical-trials-advance-novel-treatments-for-androgenetic-alopecia-as-researchers-target-30-year-treatment-gap 2025-07-24T17:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/d3c0d6efeacd898e/sanner-opens-first-u-s-manufacturing-facility-in-north-carolina-expanding-global-cdmo-operations 2025-07-24T17:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/e001ec7787cc99da/mass-general-brigham-study-links-glipizide-to-13-higher-cardiovascular-risk-in-type-2-diabetes-patients 2025-07-24T17:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/0870210f22330ebe/astra-therapeutics-secures-chf-7-75-million-to-develop-novel-anti-parasitic-drugs-for-veterinary-medicine 2025-07-24T17:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/5b47e48fcacc9d78/novartis-partners-with-matchpoint-therapeutics-in-1-billion-anti-inflammatory-drug-development-deal 2025-07-24T17:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/d33c5b536889008d/biostate-ai-expands-global-precision-medicine-platform-through-strategic-partnerships-in-us-china-and-india 2025-07-24T17:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/c6fa9791dc9ac887/stanford-study-shows-ibogaine-dramatically-reduces-ptsd-and-depression-in-veterans-with-traumatic-brain-injury 2025-07-24T17:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/fcd2acafc86eeec5/fda-grants-priority-review-for-flibanserin-expansion-to-postmenopausal-women-with-hsdd 2025-07-24T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/f5b719d0dbb45fe9/maryland-scientists-develop-shelf-stable-synthetic-blood-for-emergency-medicine 2025-07-24T17:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/955946a20887c28b/intranasal-insulin-successfully-reaches-memory-centers-in-alzheimer-s-brain-imaging-study 2025-07-24T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/4b15a76c59daf6ae/topical-immunotherapy-shows-promise-for-severe-alopecia-areata-despite-variable-response-rates 2025-07-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d64aab9d1a286cac/incyte-reports-strong-q2-2025-results-with-jakafi-growth-and-new-drug-approvals 2025-07-24T15:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/a39edf9131c3ce1c/ivermectin-mass-treatment-reduces-malaria-transmission-by-26-in-landmark-bohemia-trial 2025-07-24T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/978ee39f8038c643/medicinova-advances-dual-pipeline-strategy-with-novel-therapeutics-for-neurological-and-metabolic-disorders 2025-07-24T13:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/b52936b038545e01/turbine-partners-with-astrazeneca-to-accelerate-adc-discovery-using-ai-powered-virtual-disease-models 2025-07-24T13:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/c4de583efb987b9b/kling-bio-partners-with-sanofi-to-develop-next-generation-antiviral-antibodies-using-proprietary-b-cell-platform 2025-07-24T13:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/fef6d38a61ca477d/harvard-ai-model-pdgrapher-accelerates-drug-discovery-by-predicting-cellular-disease-reversal 2025-07-24T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/fbde7269ac1909c5/medicinova-nears-completion-of-phase-2-3-als-trial-as-combat-als-study-approaches-full-enrollment 2025-07-24T13:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/20c87b4837c7bf7d/annexin-pharmaceuticals-receives-uk-approval-for-phase-2a-study-of-anxv-in-diabetic-retinopathy 2025-07-24T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/2ad44be9beb43b21/tulsi-therapeutics-achieves-100-liver-regeneration-in-world-s-first-stem-cell-exosome-therapy-trial 2025-07-24T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/eef1e889d6528669/epilepsy-drug-pipeline-shows-robust-growth-with-90-therapies-in-development-across-75-companies 2025-07-24T09:23:39+00:00 hourly 0.9 https://trial.medpath.com/news/d1098074061915fb/dna-plasmid-therapy-elenagen-shows-90-success-rate-in-treating-chronic-pain-in-dogs-signals-non-opioid-path-for-human-medicine 2025-07-24T09:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/ec8788f8e58ad91c/llama-derived-nanobody-shows-promise-for-schizophrenia-cognitive-symptoms-in-preclinical-study 2025-07-24T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/9cd3fd32e35ee023/bridging-radiotherapy-shows-promise-in-reducing-car-t-cell-therapy-toxicity-across-b-cell-lymphoma-and-multiple-myeloma 2025-07-24T05:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/25de935d5f4c36ac/aicuris-pritelivir-achieves-superior-efficacy-in-phase-3-trial-for-refractory-hsv-in-immunocompromised-patients 2025-07-24T05:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/6bbb6c802f94bc9b/quanta-therapeutics-advances-kras-g12d-inhibitor-qtx3034-to-dose-expansion-phase-following-positive-safety-data 2025-07-24T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/82a3dbcad42668c2/pfizer-and-astellas-successfully-defend-prostate-cancer-drug-patent-against-generic-challenge 2025-07-24T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/888c8b85230d10ba/hillhurst-biopharmaceuticals-initiates-phase-2a-trial-of-oral-carbon-monoxide-therapy-for-sickle-cell-disease 2025-07-24T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/9119f79379691d3a/australia-s-national-reconstruction-fund-invests-150m-in-brandon-capital-to-retain-biotech-innovation-onshore 2025-07-24T01:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/51436ffa4bcd859e/abivax-raises-747-5-million-in-public-offering-to-advance-ulcerative-colitis-drug-development 2025-07-24T01:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/b67b181a99204823/uk-becomes-first-country-to-enable-point-of-care-manufacturing-for-personalized-therapies 2025-07-23T21:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/04ff7347fd330082/qu-biologics-completes-enrollment-in-phase-2-trial-testing-novel-immunomodulator-for-age-related-immune-decline 2025-07-23T21:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/2bac2f45e061adc5/viatris-wins-patent-battle-against-novo-nordisk-over-generic-wegovy 2025-07-23T21:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/374ed9e0e1b38977/federal-court-dismisses-whistleblower-patent-fraud-lawsuit-against-valeant-and-salix-over-ulcerative-colitis-drug-apriso 2025-07-23T21:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/3073775619923046/autoantibodies-emerge-as-key-predictors-of-cancer-immunotherapy-response-boosting-effectiveness-up-to-10-fold 2025-07-23T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/7fbef1aa7fad1d2f/fda-clears-advanced-uronav-system-for-precision-focal-therapy-in-prostate-cancer 2025-07-23T21:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/19c35571575b6c2b/stem-cell-therapy-shows-promise-for-fertility-restoration-in-women-with-ovarian-failure 2025-07-23T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/734cc6b8b69fa3e6/uc-davis-researchers-develop-gene-therapy-to-reactivate-silent-genes-in-rett-syndrome 2025-07-23T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/931328331f45ff4e/legacy-healthcare-s-cinainu-shows-sustained-hair-regrowth-in-pediatric-alopecia-areata-phase-2-3-trial 2025-07-23T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/4bc11e4ea0a858ed/atopic-dermatitis-market-poised-for-four-fold-growth-by-2034-driven-by-novel-il-13-inhibitor-approvals 2025-07-23T21:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/70f88982d12d6f27/flatiron-health-triples-global-oncology-research-network-expanding-real-world-data-access-across-three-countries 2025-07-23T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/09df2a97b0b6d49b/ucsf-chemists-overcome-solubility-issues-in-next-generation-malaria-drug-through-molecular-redesign 2025-07-23T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/8bdbebbf2679c2bd/ai-guided-drug-lp-284-achieves-complete-response-in-treatment-resistant-lymphoma-patient 2025-07-23T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/c9f115927f8258d0/long-acting-anti-tslp-antibody-hbm9378-win378-enters-global-phase-2-trial-for-asthma-treatment 2025-07-23T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/f30baf82764ad308/neuroone-receives-uspto-patent-approval-for-novel-neural-probe-manufacturing-technology 2025-07-23T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/53812d7476b4249e/huonslab-secures-key-patent-for-albumin-free-hyaluronidase-formulation-advances-toward-2026-market-authorization 2025-07-23T17:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/31eb88c9447c3743/ipsen-restructures-executive-leadership-with-three-key-appointments-to-drive-growth-in-oncology-and-rare-disease 2025-07-23T17:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/64874976f46fc8d0/former-poseida-ceo-kristin-yarema-named-to-lead-ikena-inmagene-merger-as-companies-advance-anti-ox40-therapy 2025-07-23T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/189508bdfa90d944/an2-therapeutics-partners-with-dndi-to-advance-oral-chagas-disease-treatment-an2-502998 2025-07-23T17:28:32+00:00 hourly 0.9 https://trial.medpath.com/news/13008fd694124bad/real-world-safety-data-support-mvasi-biosimilar-as-viable-alternative-for-retinal-disease-treatment 2025-07-23T17:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/4eee1814328f297d/epicore-biosystems-secures-1-2m-military-contract-for-smart-hydration-wearables 2025-07-23T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/6227a39031920410/igc-pharma-unveils-ai-powered-alzheimer-s-platforms-at-aaic-2025 2025-07-23T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/b12f5409d1702e27/oncoc4-advances-pd-1-vegf-bispecific-antibody-ai-081-to-phase-2-trial-following-promising-early-efficacy-data 2025-07-23T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/3b2301e22ac0c159/radiation-therapy-overcomes-primary-resistance-to-pembrolizumab-in-immunologically-cold-nsclc 2025-07-23T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/4eb49c8837708ea5/inotrem-s-precision-medicine-strategy-shows-breakthrough-results-for-septic-shock-treatment-with-nangibotide 2025-07-23T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/e66ae6ba42ac43e2/fda-grants-breakthrough-therapy-designation-to-avidity-s-del-zota-for-duchenne-muscular-dystrophy 2025-07-23T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/27d2c5f5fd353dab/cepi-launches-two-major-initiatives-to-accelerate-vaccine-development-and-regulatory-approval-in-disease-outbreaks 2025-07-23T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/c34d5f47231aa0ed/global-clinical-trials-landscape-for-alopecia-universalis-reveals-growing-research-activity-across-major-pharmaceutical-companies 2025-07-23T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/5504025cd8f6835c/cycle-pharmaceuticals-secures-exclusive-u-s-rights-to-phyrago-novel-dasatinib-formulation-for-leukemia-treatment 2025-07-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/381969dc4d463aeb/apollo-hospitals-and-siemens-healthineers-launch-ai-driven-research-collaboration-for-liver-disease-diagnostics-in-india 2025-07-23T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/812de0dc6e67d8e9/eisai-launches-beova-tablets-for-overactive-bladder-treatment-in-thailand 2025-07-23T13:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/d611ab63f63e5f6c/crown-bioscience-san-diego-receives-clia-certification-to-expand-clinical-testing-capabilities 2025-07-23T13:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/401c6aad51cf951e/iluvien-shows-mixed-results-in-new-day-trial-for-diabetic-macular-edema-treatment 2025-07-23T13:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/2851db75835f113e/c-mic-ii-trial-shows-microcurrent-therapy-significantly-improves-heart-function-in-heart-failure-patients 2025-07-23T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/173593afe906c473/bd-libertas-wearable-injector-enters-first-pharma-sponsored-clinical-trial-for-complex-biologics-delivery 2025-07-23T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/ab7059a02b5bbe71/bio-usawa-and-servaregmp-partner-to-establish-monoclonal-antibody-manufacturing-in-africa 2025-07-23T13:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/8abb28537a610a7a/dispatch-bio-emerges-with-216m-to-develop-universal-solid-tumor-immunotherapy 2025-07-23T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/01519eb8056d994d/dapagliflozin-demonstrates-sustained-cardiovascular-benefits-in-long-term-diabetes-study 2025-07-23T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/602ec4e7fe4ddb9b/ghana-fda-and-company-deny-coa-72-hiv-clinical-trial-claims-following-media-misinformation 2025-07-23T09:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/9b42fd536f8beb66/a-forall-launches-direct-commercialization-of-sodium-acetate-injection-to-address-u-s-drug-shortage 2025-07-23T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/dc6ac8c233ccf1ce/csl-behring-s-australian-plasma-facility-wins-global-manufacturing-excellence-award-for-advanced-automation 2025-07-23T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/a156a8e250ad246b/biocon-biologics-expands-nepexto-biosimilar-to-australian-market-for-autoimmune-disease-treatment 2025-07-23T09:22:30+00:00 hourly 0.9 https://trial.medpath.com/news/c7ad5db828e6091a/ulonivirine-shows-promise-for-once-weekly-hiv-treatment-despite-early-trial-setback 2025-07-23T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/8315ff55da741f8c/syntellix-secures-nmpa-approval-for-bioabsorbable-metallic-implants-in-china-unlocking-1-4-billion-patient-market 2025-07-23T09:21:53+00:00 hourly 0.9 https://trial.medpath.com/news/0df147be3c5309a9/pfas-forever-chemicals-linked-to-31-increased-risk-of-type-2-diabetes 2025-07-23T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/6dafc4c0f631a3ee/hesperos-achieves-first-digital-twin-of-human-disease-using-malaria-on-a-chip-platform 2025-07-23T05:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/bfc7b9c37bf945e9/american-gene-technologies-reports-sustained-hiv-reservoir-reduction-in-phase-1-trial-of-agt103-t-cell-therapy 2025-07-23T05:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/623b2083ba8dc51f/kidney-cancer-research-consortium-advances-novel-combination-therapies-through-multi-institutional-collaboration 2025-07-23T02:57:14+00:00 hourly 0.9 https://trial.medpath.com/news/513c6edaab5ebc16/avalyn-pharma-raises-100m-to-advance-inhaled-pulmonary-fibrosis-therapies 2025-07-23T01:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/6bc7a7dd34cd1a31/novel-csf-biomarkers-chit1-and-ddah1-may-predict-aria-risk-in-alzheimer-s-patients-receiving-anti-amyloid-therapies 2025-07-23T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/7ed8b60e983c5a5e/tharimmune-raises-1-74-million-to-advance-immunology-and-oncology-pipeline 2025-07-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/de501771db3fba2f/fda-approves-first-3d-printed-epilepsy-drug-for-feeding-tube-administration 2025-07-22T21:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/65e4abc3f95c076b/pacira-biosciences-partners-with-johnson-johnson-to-expand-zilretta-access-for-osteoarthritis-knee-pain 2025-07-22T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/5cfcd944af3bea11/concentra-biosciences-acquires-iteos-therapeutics-for-10-05-per-share-following-tigit-program-failure 2025-07-22T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/f2a013f751686618/stanford-researchers-develop-radiation-free-stem-cell-transplant-protocol-for-fanconi-anemia-patients 2025-07-22T21:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/864d5af80213a185/stride-immunotherapy-achieves-unprecedented-19-6-five-year-survival-rate-in-advanced-liver-cancer 2025-07-22T21:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/1c9645d0fdb28ca7/subcutaneous-daratumumab-formulation-reduces-treatment-time-and-premedication-requirements-in-multiple-myeloma 2025-07-22T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/e807f9b71d6d6198/hmnc-brain-health-and-spruce-biosciences-launch-phase-2-trial-for-precision-depression-treatment 2025-07-22T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/a1861b8b902d4c55/precision-genomic-profiling-reveals-multiple-molecular-diagnoses-in-gaucher-disease-patients-with-atypical-presentations 2025-07-22T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/3fd50334ba53ad3e/real-world-study-shows-adalimumab-biosimilar-ibi303-matches-humira-efficacy-with-superior-cost-benefits-in-ankylosing-spondylitis 2025-07-22T21:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/d60f4a8716452bd2/fda-rejects-replimune-s-melanoma-drug-amid-evolving-regulatory-standards 2025-07-22T21:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/bf5afec82eb9e4d2/nanoknife-system-shows-promise-for-prostate-cancer-treatment-in-preserve-trial 2025-07-22T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/bc8a8ee98cf0930b/sintx-technologies-submits-fda-510-k-for-silicon-nitride-foot-and-ankle-implants 2025-07-22T21:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/2d6bf5f1595204be/wuxi-biologics-achieves-100-fda-inspection-success-rate-with-five-facilities-passing-pre-license-review 2025-07-22T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/cfc1d78fb394e1cd/radiopharm-theranostics-appoints-leading-prostate-cancer-expert-dr-oliver-sartor-to-scientific-advisory-board 2025-07-22T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/38fdfc4e5b2f6f4b/cdsco-approves-phase-iii-trials-for-two-novel-cardiovascular-fixed-dose-combinations 2025-07-22T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/fd954c6e5bdfeb39/biovie-strengthens-board-with-neuroscience-and-finance-veterans-as-bezisterim-advances-through-phase-2-trials 2025-07-22T17:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/fd4b691676664205/cgt-catapult-invests-in-spliceor-s-trans-splicing-gene-therapy-platform-for-liver-cancer 2025-07-22T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/8efde3091aa36a4d/first-patient-receives-gene-therapy-for-ultra-rare-nedamss-disease-in-record-13-month-timeline 2025-07-22T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/1ba037bc38f59170/ixico-secures-full-data-rights-to-landmark-bio-hermes-002-alzheimer-s-study-through-strategic-gap-partnership 2025-07-22T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/6409cb27745701b3/fda-discontinues-rare-pediatric-disease-designation-program-despite-rising-approval-trends 2025-07-22T17:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/2ba5af718fd9fb83/alto-neuroscience-faces-class-action-lawsuit-following-alto-100-phase-2b-trial-failure 2025-07-22T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/fa90754089fa4cb4/medunik-usa-expands-siklos-r-medicaid-coverage-to-37-states-improving-access-for-sickle-cell-disease-patients 2025-07-22T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/50dd502408e66129/coriolis-pharma-invests-10-million-in-north-carolina-laboratory-to-expand-biopharmaceutical-development-services 2025-07-22T17:25:57+00:00 hourly 0.9 https://trial.medpath.com/news/b14a805540e67cf5/q3-2025-biopharma-catalyst-monitor-highlights-18-key-fda-decisions-and-clinical-trial-milestones 2025-07-22T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/3b214ec1e152aec1/surgivance-secures-2-2m-nih-grant-to-advance-direct-to-digital-pathology-platform 2025-07-22T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/e71f4fcd5fad2e7f/seres-therapeutics-appoints-co-ceos-as-company-seeks-partnerships-for-ser-155-development 2025-07-22T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/8bae1ff4a37d29a1/estonian-biotech-aio-secures-eur1m-grant-to-develop-sustainable-cosmetics-ingredients-through-yeast-fermentation 2025-07-22T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/4464438b81c09495/answer-als-launches-ai-powered-drug-discovery-initiative-to-accelerate-als-treatment-development 2025-07-22T17:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/6c2e9896d1c31105/sutro-biopharma-partners-with-fda-to-establish-regulatory-standards-for-antibody-drug-conjugates 2025-07-22T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/963188b176bc71e7/osteochondral-organoids-emerge-as-breakthrough-platform-for-osteoarthritis-research-and-therapy 2025-07-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/836f85799c760400/cooler-heads-raises-11m-series-a-to-expand-fda-cleared-scalp-cooling-system-for-chemotherapy-patients 2025-07-22T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/0686bcc4fc4e0a62/supreme-court-of-canada-to-rule-on-medical-treatment-patent-eligibility-in-landmark-pharmascience-v-janssen-case 2025-07-22T13:23:51+00:00 hourly 0.9 https://trial.medpath.com/news/117ab79dafa93718/fda-requests-additional-manufacturing-data-for-telix-s-kidney-cancer-diagnostic-drug-zircaix 2025-07-22T13:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/5134f04c3137a677/iovance-biotherapeutics-shares-surge-14-on-amtagvi-fda-approval-and-new-ceo-appointment 2025-07-22T13:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/4c58c925fe975bf1/phoremost-unveils-glueseeker-platform-to-accelerate-rational-molecular-glue-drug-discovery 2025-07-22T13:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/dde51e40efe016e7/eyam-health-and-mmv-partner-to-develop-1-malaria-prevention-shot-using-ai-designed-monoclonal-antibodies 2025-07-22T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/070a63bcf34fb3b5/fda-issues-complete-response-letter-for-replimune-s-rp1-melanoma-therapy-citing-trial-design-concerns 2025-07-22T13:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/5087ac998298fefd/sanofi-acquires-vicebio-for-1-15-billion-to-expand-respiratory-vaccine-pipeline-with-molecular-clamp-technology 2025-07-22T13:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/3334faa669bdaca8/failed-long-covid-drug-trial-reveals-critical-study-design-flaws-as-new-company-plans-restart 2025-07-22T13:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/022e2865a798bcf3/new-clinical-trials-market-reports-highlight-global-research-landscape-for-vitamin-b12-deficiency-and-hypoglycemia 2025-07-22T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/db08d8fcbd336d9f/lantheus-completes-789-million-acquisition-of-life-molecular-imaging-gains-fda-approved-alzheimer-s-diagnostic-agent 2025-07-22T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/93e3546bcb7226bd/nyxoah-receives-fda-approval-for-genio-neuromodulation-device-to-treat-sleep-apnea 2025-07-22T09:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/5c54983993e6a242/daewoong-pharmaceutical-enters-biosimilar-market-with-former-celltrion-executive-leading-new-division 2025-07-22T09:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/6b59429b3c1c27ff/zepbound-receives-health-canada-approval-as-first-dual-receptor-obesity-treatment 2025-07-22T09:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/40c2654b56e7ef2c/eli-lilly-advances-loxo-435-in-phase-1-forager-1-study-for-fgfr3-altered-advanced-cancers 2025-07-22T05:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/3e4bbd774c19fa56/survey-reveals-patient-priorities-in-advanced-colorectal-cancer-treatment-decision-making 2025-07-22T05:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/2237f0e8a2088e33/iovance-biotherapeutics-expands-workforce-with-stock-option-grants-for-new-employees 2025-07-22T02:55:37+00:00 hourly 0.9 https://trial.medpath.com/news/10ae566dbabf540d/longeveron-licenses-novel-cardiac-stem-cell-technology-to-address-safety-concerns-in-heart-disease-treatment 2025-07-22T01:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/97b9f28dd5269e53/hiv-drugs-show-promise-as-first-prophylactic-treatment-for-htlv-1-virus-in-landmark-australian-study 2025-07-22T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/25c5aecb05be0c2a/dualitybio-s-her3-targeting-adc-db-1310-receives-fda-fast-track-designation-for-egfr-mutant-lung-cancer 2025-07-22T01:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/51074880fbabbeee/astrazeneca-announces-50-billion-us-investment-plan-with-virginia-manufacturing-hub-for-weight-management-and-metabolic-drugs 2025-07-22T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/f3cd73347b167fe9/casi-pharmaceuticals-names-david-cory-ceo-to-advance-anti-cd38-antibody-cid-103-program 2025-07-22T01:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/9997ed0a10244862/fda-clears-takeda-s-hyhub-devices-to-streamline-at-home-hyqvia-immunoglobulin-therapy 2025-07-22T01:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/95df8350207fc9b4/extended-paxlovid-treatment-reduces-viral-rebound-in-immunocompromised-covid-19-patients 2025-07-21T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/33cf337ea7e20424/livzon-s-dual-target-il-17a-f-antibody-lzm012-outperforms-secukinumab-in-phase-iii-psoriasis-trial 2025-07-21T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/83fbcc14fb2fa373/covid-19-vaccine-effectiveness-studies-show-waning-protection-over-time-supporting-annual-vaccination 2025-07-21T21:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/8ca5bbd7a09e182f/fda-expert-panel-debates-ssri-safety-during-pregnancy-amid-calls-for-stronger-warnings 2025-07-21T21:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/18f83e3ad54597c4/ausperbio-receives-china-cde-clearance-for-phase-iii-trial-of-hepatitis-b-antisense-therapy-ahb-137 2025-07-21T21:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/cd290f6b232a1e60/nestmedic-partners-with-curavit-for-u-s-clinical-trial-of-ai-enabled-prenatal-monitoring-device 2025-07-21T21:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/cdf2fabed56b37c9/landmark-study-challenges-decades-of-cholesterol-concerns-about-eggs 2025-07-21T17:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/e9496e2935f53eab/harmony-trial-introduces-adaptive-parp-inhibitor-strategy-for-metastatic-prostate-cancer-with-focus-on-underrepresented-populations 2025-07-21T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/a47e2ff998c05cbc/nanogel-armed-car-t-cells-achieve-83-2-tumor-inhibition-rate-in-solid-tumor-model 2025-07-21T17:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/82d30c0e2df038de/cytomed-therapeutics-advances-novel-car-gamma-delta-t-cell-therapy-to-phase-i-dose-level-2 2025-07-21T17:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/d3e4fa2fdf51fa44/promis-neurosciences-receives-fda-fast-track-designation-for-alzheimer-s-drug-pmn310 2025-07-21T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/719bc27269a9e125/epirium-bio-completes-first-in-human-trial-of-novel-oral-sarcopenia-treatment-mf-300 2025-07-21T17:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/bc9f91ed223028e0/medgenome-secures-47-5-million-series-e-funding-to-expand-genomic-diagnostics-access-across-india 2025-07-21T17:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/a680b9a4277d1530/diamedica-therapeutics-secures-30-1-million-to-advance-dm199-for-preeclampsia-and-fetal-growth-restriction 2025-07-21T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/99ff23ebe9221558/lantern-pharma-secures-european-patent-for-ai-developed-cancer-therapy-lp-284 2025-07-21T17:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/c8dd75f84b60a092/eli-lilly-s-orforglipron-shows-promise-as-oral-glp-1-therapy-advances 2025-07-21T17:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/81a50dfc39ac4ad0/mvp-health-care-partners-with-renalytix-to-expand-access-to-ai-powered-kidney-disease-testing 2025-07-21T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/fa9355ea9c674d37/korro-bio-receives-ema-orphan-drug-designation-for-rna-editing-therapy-krro-110-in-alpha-1-antitrypsin-deficiency 2025-07-21T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/382d11b5513cb066/redhill-biopharma-receives-fda-approval-for-groundbreaking-map-targeted-crohn-s-disease-study 2025-07-21T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/7d16fad0d14740b1/cerus-corporation-secures-7-2m-dod-contract-amendment-to-advance-trauma-hemorrhage-treatment 2025-07-21T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/5fe3affddf0100e6/fda-appoints-biotech-veteran-george-tidmarsh-to-lead-drug-regulation-center-amid-agency-restructuring 2025-07-21T13:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/91700c64f5e4d6fc/gecko-inspired-nanoparticles-show-promise-for-targeted-bladder-cancer-therapy 2025-07-21T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/4461ba04342663b3/ima-group-acquires-medical-research-network-to-expand-cns-clinical-trial-capabilities 2025-07-21T13:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/60548869a39bd6a3/corteria-pharmaceuticals-advances-first-in-class-crf2-agonists-into-phase-2-heart-failure-and-phase-1-obesity-trials 2025-07-21T13:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/4f1816a15a49434d/nice-approves-first-in-class-birch-pollen-immunotherapy-for-severe-hayfever-on-nhs 2025-07-21T13:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/c1fdec3141ff127c/alk-s-tree-pollen-tablet-itulazax-receives-nice-recommendation-for-uk-nhs-reimbursement 2025-07-21T13:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/6ecfc9af5259da45/sab-bio-secures-175-million-funding-to-advance-type-1-diabetes-immunotherapy-through-phase-2b-trial 2025-07-21T13:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/8ec09d477b5b06f1/abu-dhabi-investment-authority-invests-200-million-in-indian-medtech-company-meril 2025-07-21T13:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/c0885266f926836a/alkermes-alixorexton-shows-promise-in-phase-2-narcolepsy-trial-achieving-normal-wakefulness-levels 2025-07-21T13:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/58374261f85ad232/omega-funds-closes-oversubscribed-647m-fund-viii-to-accelerate-life-sciences-innovation 2025-07-21T13:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/2c09f53638b3602e/japanese-researchers-develop-gai-17-novel-stroke-drug-with-six-hour-treatment-window 2025-07-21T13:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/5e51e9ca32414d5b/donidalorsen-shows-62-reduction-in-hae-attacks-when-patients-switch-from-other-prophylactics-in-phase-3-study 2025-07-21T13:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/4ebc987bbe73d654/oncozenge-partners-with-meribel-pharma-for-bupizenge-phase-3-manufacturing 2025-07-21T13:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/8ddbad1df9a1531a/xvivo-initiates-us-continued-access-protocol-study-for-heart-assist-transport-device-following-successful-preserve-trial 2025-07-21T13:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/c626a32a361336b7/brisk-walking-shows-significant-health-benefits-in-large-scale-studies-of-older-adults 2025-07-21T10:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/50f999ec3c0f5944/fda-regulatory-changes-drive-strategic-timing-considerations-and-medical-affairs-team-adaptations 2025-07-21T09:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/c2be353099135eb5/cdsco-releases-new-sec-guidelines-to-enhance-drug-and-medical-device-approval-process 2025-07-21T09:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/66f0fb21dc71feb8/fangzhou-and-novo-nordisk-partner-to-create-ai-powered-chronic-disease-management-ecosystem-in-china 2025-07-21T09:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/7e5b8c270229dfe7/ai-repurposed-diabetes-drug-halicin-shows-promise-against-multidrug-resistant-superbugs 2025-07-21T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/d4fc7eb71254d45b/sun-pharma-s-ilumya-achieves-primary-endpoints-in-two-phase-3-psoriatic-arthritis-trials 2025-07-21T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/ae2e1336eb4fcc20/abbvie-acquires-gilgamesh-s-breakthrough-depression-treatment-bretisilocin-for-1-2-billion 2025-07-21T09:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/56e12d6d356eda38/corestemchemon-partners-with-atg-lifetech-to-advance-organoid-based-preclinical-testing 2025-07-21T09:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/09528143d02cbe4f/cloudbreak-pharma-s-cbt-004-achieves-primary-endpoint-in-phase-2-trial-for-vascularized-pinguecula 2025-07-21T09:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/85d7cf2c3aa5308b/roche-s-astegolimab-shows-mixed-results-in-copd-trials-phase-iib-study-meets-primary-endpoint 2025-07-21T09:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/41cccab2a94f1eb6/venus-remedies-receives-who-gdp-certification-for-advanced-digital-logistics-operations 2025-07-21T09:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/084fa13b7c79f9df/nhs-launches-new-glioblastoma-trial-after-patient-shows-complete-tumor-clearance-with-ipilimumab 2025-07-21T09:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/34e4a36dd5823c04/japanese-researchers-begin-human-trials-for-revolutionary-tooth-regeneration-drug 2025-07-21T09:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/c7b4e6c9ba70656f/protalix-biotherapeutics-appoints-gilad-mamlok-as-new-cfo-to-drive-growth-strategy 2025-07-21T03:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/b192dbd6acb346f3/engineered-gut-bacteria-shows-promise-in-phase-1-2a-trial-for-kidney-stone-prevention 2025-07-21T02:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b27376a30fd391a/novel-evobody-bispecific-antibodies-show-promise-in-ovarian-cancer-by-targeting-vg9vd2-t-cells 2025-07-20T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/cd82f66a1942d733/fda-panel-overwhelmingly-rejects-otsuka-s-ptsd-drug-combination-in-10-1-vote 2025-07-20T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/ca1458ec341d30f7/positive-trial-shows-breastfeeding-safe-for-women-with-hr-positive-breast-cancer-after-treatment-interruption 2025-07-20T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/4f58fb6e87eaa414/india-develops-indigenous-multi-stage-malaria-vaccine-adfalcivax-targeting-dual-parasite-protection 2025-07-20T17:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/0872340be529cb37/community-pharmacies-emerge-as-key-players-in-pharmacogenetic-testing-implementation 2025-07-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c0225081827f8c5/delhi-high-court-grants-interim-injunction-against-zydus-biosimilar-to-protect-nivolumab-patent-rights 2025-07-20T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/c16d2a770b8b3212/oncologists-prescribe-cancer-drugs-23-times-more-after-fda-accelerated-approval-than-traditional-approval 2025-07-20T13:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/cd426ebef2d96992/turkish-study-links-pfizer-covid-19-vaccine-to-corneal-structural-changes 2025-07-20T09:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/e6d4ce518bd6305c/onto-innovation-acquires-semilab-s-materials-analysis-business-for-545-million-to-expand-semiconductor-process-control-portfolio 2025-07-20T01:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/467400126aa741ba/congressional-budget-office-warns-trump-s-proposed-nih-cuts-could-reduce-drug-approvals-by-4-5 2025-07-20T01:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/1d19befb10021815/upc-ruling-protects-generic-drug-development-zentiva-wins-marketing-authorization-case-against-boehringer-ingelheim 2025-07-20T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/98efc23fc392e11f/blinatumomab-achieves-unprecedented-96-97-success-rate-in-pediatric-b-cell-all-treatment 2025-07-20T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/251af0d0a3c1fa78/b-c-government-reverses-funding-decision-for-rare-disease-treatment-after-expert-committee-resignations 2025-07-19T21:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/a9d71f20e7e949e2/chinese-scientists-achieve-first-in-human-in-vivo-car-t-therapy-using-genetically-modified-virus 2025-07-19T21:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/381af8c92777dc68/real-world-analysis-reveals-unexpected-safety-signals-for-temozolomide-in-glioma-treatment 2025-07-19T21:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/16c717a73da746a7/cochlear-receives-fda-approval-for-world-s-first-smart-cochlear-implant-with-upgradeable-firmware 2025-07-19T21:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/3b46a44344d9a3f2/long-term-obesity-accelerates-biological-aging-in-young-adults-study-finds 2025-07-19T21:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/11e9ee11166e3bf1/panjab-university-researchers-patent-magnetic-lignin-nano-constructs-for-advanced-3d-cancer-cell-culture 2025-07-19T16:59:10+00:00 hourly 0.9 https://trial.medpath.com/news/35229e9e1cd43e53/gsk-advances-dostarlimab-in-phase-3-colon-cancer-trial-and-phase-2-endometrial-cancer-study 2025-07-19T16:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/21c116bc1084f1e5/tibsovo-listed-on-australian-pbs-offering-first-targeted-therapy-for-rare-bile-duct-cancer 2025-07-19T13:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/4876c08a3cb6b39e/cd163-tumor-associated-macrophages-linked-to-improved-nivolumab-outcomes-in-metastatic-renal-cell-carcinoma 2025-07-19T13:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/205f16079a4e82c8/abivax-phase-3-data-positions-company-for-multi-billion-dollar-market-opportunity 2025-07-19T06:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/9d47e5ec7b12cd89/champions-oncology-appoints-rob-brainin-as-new-ceo-to-drive-data-platform-expansion 2025-07-19T05:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/df3d5adf2d5f72f7/novartis-reports-strong-q2-2025-results-with-kisqali-leading-64-growth-surge 2025-07-19T02:55:52+00:00 hourly 0.9 https://trial.medpath.com/news/28f202ed477d920a/amphastar-pharmaceuticals-plans-to-quadruple-us-manufacturing-capacity-in-major-domestic-expansion 2025-07-19T01:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/827c428a4912f2ba/fda-approves-osilodrostat-for-second-line-cushing-syndrome-treatment-as-pipeline-advances 2025-07-19T01:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/42e42dc663b17787/nanopharmaceutics-completes-phase-ii-enrollment-for-triapine-combination-therapy-in-neuroendocrine-tumors 2025-07-19T01:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/713420ec9267b915/nuwellis-terminates-reverse-hf-clinical-trial-to-refocus-on-outpatient-heart-failure-market 2025-07-18T21:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/380271e18a37e2d9/australian-researchers-develop-pan-coronavirus-vaccine-candidate-with-99-9-protection-against-multiple-variants 2025-07-18T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/e659ab01fbd9c419/fda-approves-exzolt-first-oral-treatment-for-northern-fowl-mites-in-poultry 2025-07-18T21:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/13584e3fdea07021/biontech-chief-strategy-officer-ryan-richardson-to-step-down-after-seven-year-tenure 2025-07-18T21:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/e6da82a74b188030/university-of-guelph-develops-canada-s-first-mrna-bird-flu-vaccine-for-commercial-poultry 2025-07-18T21:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/66295068a3e042a1/medtronic-wins-appeal-overturns-106-5-million-patent-infringement-verdict-in-heart-valve-case 2025-07-18T21:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/ea9cab1916ed4dc3/extended-half-life-factor-viii-therapy-reduces-bleeding-episodes-and-injection-frequency-in-hemophilia-a-patients 2025-07-18T21:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/6b161cb6b9ce0604/telomir-1-outperforms-standard-chemotherapy-in-reversing-cancer-gene-silencing 2025-07-18T21:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/3ef380f59195e931/emerging-dry-eye-therapies-show-promise-blood-serum-drops-and-neuromodulation-lead-innovation-pipeline 2025-07-18T17:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/40e82fa41d140a83/knight-therapeutics-files-new-drug-submission-for-crexont-in-canada-following-successful-phase-3-trial 2025-07-18T17:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/1aa57cca77a714ec/ojjaara-shows-superior-anemia-control-in-myelofibrosis-achieving-67-transfusion-independence-rate 2025-07-18T17:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/0bb8875b33394357/metastasis-directed-radiotherapy-shows-durable-disease-control-in-oligometastatic-renal-cell-carcinoma-without-systemic-therapy 2025-07-18T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/30cccfcf8ef3cb88/lexicon-pharmaceuticals-presents-patient-reported-data-on-diabetic-peripheral-neuropathic-pain-at-aspn-2025 2025-07-18T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/8a890f990c6c9a37/belzutifan-demonstrates-superior-quality-adjusted-survival-time-compared-to-everolimus-in-advanced-renal-cell-carcinoma 2025-07-18T17:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/11e7482b1a35994d/processa-pharmaceuticals-advances-pcs6422-in-phase-2-breast-cancer-trial-with-7-million-funding-boost 2025-07-18T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/c2500173e2eb7d6f/filgrastim-biosimilars-demonstrate-15-million-cost-savings-potential-in-cancer-care 2025-07-18T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/73c505ac4c372ba9/aenova-expands-irish-facility-to-tackle-drug-bioavailability-challenge-with-advanced-spray-drying-technology 2025-07-18T17:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/68e5d35c99eeb3cb/hengrui-medicine-advances-cancer-pipeline-with-breakthrough-therapy-designations-and-clinical-trial-approvals 2025-07-18T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/ab52f5799b931784/bristol-myers-squibb-s-reblozyl-fails-primary-endpoint-in-phase-iii-myelofibrosis-trial-despite-secondary-benefits 2025-07-18T17:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/6d80749ee50ae597/pediatric-hidradenitis-suppurativa-shows-superior-response-to-adalimumab-over-infliximab-in-real-world-study 2025-07-18T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/f4ccb36e390dbe41/telomir-pharmaceuticals-lead-compound-shows-promise-in-reversing-cancer-gene-silencing 2025-07-18T13:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/84bbc34ab21ff0b9/abvc-biopharma-receives-150k-milestone-payment-advancing-botanical-cns-therapies-through-strategic-partnerships 2025-07-18T13:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/f9a960b7f1d03ea8/moderna-cancels-mrna-manufacturing-plant-in-japan-amid-declining-vaccine-demand-and-regulatory-uncertainty 2025-07-18T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/68e2c049e1478c89/university-of-florida-researchers-develop-universal-mrna-cancer-vaccine-that-awakens-immune-system 2025-07-18T13:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/65615dfa71e00183/german-researchers-develop-gallium-complex-that-triggers-immunogenic-cell-death-to-combat-cancer-metastases 2025-07-18T13:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/4ab18d30f0a3971b/btk-inhibitors-challenge-traditional-ms-coverage-models-as-payers-seek-evidence-based-alternatives-to-step-therapy 2025-07-18T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/b87301fa327de5bc/nuclear-waste-from-manhattan-project-transformed-into-breakthrough-cancer-treatment-at-oak-ridge 2025-07-18T09:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/86ed9bb0461fbede/4dmedical-advances-respiratory-imaging-technology-with-university-partnership-extension-and-ai-development-grant 2025-07-18T09:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/6b1b45b064b9b361/trogenix-strengthens-leadership-team-with-key-clinical-appointments-as-odysseus-platform-advances-toward-clinical-trials 2025-07-18T09:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/de3c5dcc649ba107/deepqure-receives-mfds-approval-for-atrial-fibrillation-trial-of-novel-laparoscopic-renal-denervation-system 2025-07-18T09:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/e05795de6b0e270a/biomedit-advances-first-in-class-probiotic-antibody-platform-with-18-4m-series-b-funding 2025-07-18T09:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/aed1e9d308864913/five-year-pharmacovigilance-study-confirms-safety-of-ntc-s-fixed-dose-eye-drops-for-post-cataract-surgery 2025-07-18T09:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/fd7de974e13247aa/type-1-diabetes-pipeline-shows-robust-growth-with-85-companies-developing-100-therapeutic-candidates 2025-07-18T05:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/8a0a7206dbf4f569/amgen-advances-phase-3-study-of-etelcalcetide-for-pediatric-secondary-hyperparathyroidism 2025-07-18T05:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/c4cea8f8b7fd4391/immunotherapy-combinations-transform-advanced-squamous-cell-anal-cancer-treatment-landscape 2025-07-18T03:55:16+00:00 hourly 0.9 https://trial.medpath.com/news/6d16a15264050e85/galderma-reports-nine-month-efficacy-data-for-combined-sculptra-and-restylane-treatment-in-glp-1-associated-facial-volume-loss 2025-07-18T01:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/f537359d01ab275d/covid-19-boosters-reduce-hospitalization-risk-by-29-in-cancer-patients-large-multi-center-study-shows 2025-07-18T01:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/a14a2c1a14b87292/british-columbia-restricts-sales-of-diabetes-drugs-tirzepatide-and-dulaglutide-to-combat-weight-loss-driven-shortages 2025-07-18T01:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/eea913d7a5302830/eledon-pharmaceuticals-to-present-updated-phase-1b-kidney-transplant-data-for-tegoprubart-at-world-transplant-congress-2025 2025-07-18T01:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/09aec4e78e3f99a6/neurogen-biomarking-to-present-validation-data-for-at-home-alzheimer-s-blood-biomarker-test-at-aaic-2025 2025-07-18T01:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/2de881eb85e4b89e/avacta-therapeutics-raises-ps3-25-million-and-secures-bond-amendment-to-advance-fap-dox-cancer-therapy 2025-07-18T01:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/fd92838c7d6103df/canadian-real-world-study-shows-comparable-remission-rates-between-etanercept-biosimilars-and-originator-in-rheumatoid-arthritis 2025-07-18T01:20:36+00:00 hourly 0.9 https://trial.medpath.com/news/0d5099051ef6b75a/nihr-pilots-just-in-time-clinical-trial-initiative-for-pancreatic-cancer-using-pembrolizumab-olaparib-combination 2025-07-18T01:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/3ac7b7ca9c1a01c3/fda-expert-panel-calls-for-revision-of-menopausal-hormone-therapy-warning-labels 2025-07-18T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/e8c8770a9f7c9746/acute-ischemic-stroke-pipeline-shows-promise-with-25-therapies-in-development-and-recent-clinical-breakthroughs 2025-07-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0cbe9785c2edef25/microbiome-signatures-in-blood-and-gut-emerge-as-promising-biomarkers-for-colorectal-cancer-detection 2025-07-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b9a7bc5938579dc4/multi-cancer-detection-blood-tests-enter-major-clinical-trial-across-virginia-and-missouri 2025-07-17T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/2a21c4e31b0be03d/fda-advisory-panel-rejects-gsk-s-blenrep-combination-therapies-for-multiple-myeloma 2025-07-17T21:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/25cb50f97928970d/robotic-assisted-aneurysm-embolization-achieves-94-technical-success-rate-in-six-month-follow-up-study 2025-07-17T21:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/eacab71359b60595/aspect-biosystems-bioprinted-adrenal-tissues-show-promise-for-primary-adrenal-insufficiency-treatment 2025-07-17T21:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/95d2708cf6564018/biohaven-advances-troriluzole-in-phase-2-3-trial-for-treatment-resistant-ocd-as-pipeline-expands 2025-07-17T21:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/4e750d7a47e01079/fda-authorizes-juul-e-cigarettes-for-continued-market-sale-after-multiyear-review 2025-07-17T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/42ddd3c0bcfdbe53/fda-approved-rectal-cancer-drug-metric-fails-to-predict-long-term-survival-tulane-study-finds 2025-07-17T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/314115fe94976af9/ambulatory-pharmacists-emerge-as-key-players-in-value-based-care-models-to-address-rising-drug-costs 2025-07-17T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/575fafaab77b6072/pfizer-recalls-bicillin-l-a-due-to-contamination-threatening-syphilis-treatment-amid-rising-congenital-cases 2025-07-17T17:38:37+00:00 hourly 0.9 https://trial.medpath.com/news/73e318abcd82f83a/fda-ends-rare-pediatric-disease-designation-program-after-decade-of-mixed-results 2025-07-17T17:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/dc7205f9e370e0b5/citizens-petition-seeks-fda-accelerated-approval-for-nurown-stem-cell-therapy-in-als-based-on-survival-data 2025-07-17T17:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/af5dda4a1d99d87b/renovaro-s-engineered-dendritic-cell-therapy-achieves-81-7-tumor-reduction-in-pancreatic-cancer-models 2025-07-17T17:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/23e91c484e9230f7/nanjing-leads-biolabs-soars-122-on-hong-kong-debut-following-hk-1-1-billion-ipo 2025-07-17T17:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/a4b6430fbf15294f/brazil-s-patent-landscape-transformation-supreme-court-ruling-reshapes-pharmaceutical-ip-strategy 2025-07-17T17:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/d31d9b8c53705330/one-biosciences-secures-eur15-million-series-a-to-advance-ai-powered-single-cell-cancer-diagnostics-platform 2025-07-17T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/8763eb87c257b28c/keros-therapeutics-initiates-phase-3-renew-trial-for-elritercept-in-myelodysplastic-syndromes-triggers-10m-takeda-milestone 2025-07-17T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/e64eeab3a780ef0f/seaport-therapeutics-initiates-phase-2b-trial-of-novel-oral-antidepressant-glyphallo 2025-07-17T17:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/4b80a5b1e395c64c/moma-therapeutics-initiates-first-in-human-trial-of-werner-helicase-inhibitor-moma-341-for-msi-h-solid-tumors 2025-07-17T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/c14d0e242a630680/lisata-therapeutics-reports-promising-60-response-rate-in-pancreatic-cancer-trial-with-certepetide 2025-07-17T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/6d784d93f372c46b/harrow-secures-exclusive-us-rights-to-samsung-bioepis-ophthalmology-biosimilars-portfolio 2025-07-17T17:27:56+00:00 hourly 0.9 https://trial.medpath.com/news/bf99dde5195ad29e/i-mab-acquires-bridge-health-biotech-to-strengthen-givastomig-bispecific-antibody-development 2025-07-17T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/0e391d96c2aade5b/regen-biopharma-prepares-phase-i-trial-for-hemaxellerate-stem-cell-therapy-targeting-severe-aplastic-anemia 2025-07-17T17:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/5ac2d15513d426f5/diamedica-s-dm199-shows-promising-blood-pressure-reduction-in-phase-2-preeclampsia-trial 2025-07-17T17:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/e4def143ee9d38b0/cube-biotech-appoints-michael-bencak-as-new-ceo-to-drive-global-expansion-in-protein-technologies 2025-07-17T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/news/4556825829790575/uromems-receives-fda-and-ansm-clearance-for-pivotal-trial-of-smart-artificial-urinary-sphincter 2025-07-17T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/3d1198bf3c7e686c/fifty1-labs-partners-with-biospark-ai-to-accelerate-drug-repurposing-through-advanced-literature-mining 2025-07-17T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/3ca036ea973aa744/moleculin-appoints-roche-veteran-adriano-treve-as-strategic-advisor-ahead-of-phase-3-aml-trial-data 2025-07-17T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/7d5f31deab09f018/vor-bio-appoints-telitacicept-development-expert-dr-qing-zuraw-as-chief-development-officer 2025-07-17T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/0123bcf3b188f325/congressional-lawmakers-push-for-fast-track-approval-of-antiparasitic-treatments-as-new-world-screwworm-threat-approaches-u-s-border 2025-07-17T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/01ef9a07393aeb18/saluda-medical-launches-eva-sensing-technology-for-personalized-spinal-cord-stimulation-in-u-s 2025-07-17T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/04d84db6f39acaac/trivarx-advances-ai-powered-depression-screening-with-veterans-affairs-clinical-trial 2025-07-17T17:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/696b9ae43256fe21/bristol-myers-squibb-and-pfizer-launch-direct-to-patient-eliquis-program-with-40-price-discount 2025-07-17T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/757ba70fcae2d7a2/velocity-clinical-research-partners-with-palantir-to-automate-clinical-trial-payment-reconciliation-using-ai 2025-07-17T17:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/c707bad3f10808f0/10x-genomics-partners-with-singapore-institute-to-launch-ai-driven-cancer-drug-discovery-study 2025-07-17T17:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/15fb4fc9387c2047/ginkgo-bioworks-launches-automated-adme-profiling-service-to-accelerate-small-molecule-drug-discovery 2025-07-17T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/01f4b788443b237f/organoid-technology-advances-diabetes-research-with-sophisticated-3d-models-and-therapeutic-applications 2025-07-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7323a90295ac3978/bedtime-blood-pressure-medication-dosing-shows-superior-nighttime-control-in-chinese-trial 2025-07-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f81d380e09ece362/ema-grants-orphan-drug-designations-for-fragile-x-syndrome-and-radiation-induced-maculopathy-treatments 2025-07-17T14:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/e505e52708c97793/bird-foundation-approves-additional-funding-for-itol-102-type-1-diabetes-cell-therapy-following-fda-pre-ind-meeting 2025-07-17T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/221355f5e212b1f1/jaya-biosciences-secures-key-asian-patents-for-novel-alzheimer-s-gene-therapy-targeting-lysosomal-enzyme-defects 2025-07-17T13:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/c9dd453335cebefd/european-court-cancels-biogen-s-extended-market-exclusivity-for-multiple-sclerosis-drug-tecfidera 2025-07-17T13:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/8845c5e15bb8e9a9/hansa-biopharma-secures-24-3m-funding-as-idefirix-sales-surge-76-in-q2-2025 2025-07-17T13:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/cc68f6e33aa53965/mmj-international-ceo-alleges-dea-obstruction-of-fda-authorized-cannabis-research-for-neurological-diseases 2025-07-17T13:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/0539e1897268eb29/newer-antiseizure-medications-show-improved-safety-profile-during-pregnancy 2025-07-17T10:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/419189a65f525359/nanochon-receives-health-canada-approval-for-first-in-human-trial-of-3d-printed-knee-cartilage-implant 2025-07-17T09:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/c921f451f5ebb27f/car-t-cell-therapy-proves-safe-and-effective-for-octogenarians-with-b-cell-lymphoma 2025-07-17T09:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/9cc25d37b1e61731/cosmo-pharmaceuticals-launches-first-in-class-acne-treatment-winlevi-in-southeast-asia 2025-07-17T09:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/1d62671e64f55953/sarepta-therapeutics-implements-400-million-cost-cutting-plan-amid-regulatory-challenges-for-gene-therapy 2025-07-17T05:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/61960d9f316e3daa/ihc-testing-enables-rapid-tp53-mutation-detection-in-mds-and-aml-patients 2025-07-17T05:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/6e6425e0e3a710e4/aav-gene-therapy-pipeline-expands-with-180-companies-developing-250-treatments-despite-recent-setbacks 2025-07-17T03:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/ba45d4fb857e728e/pharma-industry-adapts-strategic-drug-development-amid-funding-crisis-and-regulatory-uncertainty 2025-07-17T02:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/e532a7b31a1be422/fda-implements-major-workforce-reduction-and-policy-changes-amid-regulatory-overhaul 2025-07-17T02:56:36+00:00 hourly 0.9 https://trial.medpath.com/news/70507a55c01b9876/johnson-johnson-strengthens-neuroscience-portfolio-with-14-6-billion-intra-cellular-acquisition 2025-07-17T01:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/e7b0b16adc53315d/openevidence-raises-210-million-series-b-to-expand-ai-powered-medical-research-platform-for-physicians 2025-07-17T01:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/a59dbb2f7bc8bc89/yale-researchers-engineer-novel-antibody-rna-therapy-platform-for-treatment-resistant-cancers 2025-07-17T01:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/f6a54f84fc352615/eight-healthy-babies-born-in-britain-using-three-person-dna-technique-to-prevent-mitochondrial-disease 2025-07-17T01:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/0768c3c009e91680/csir-launches-nationwide-phenome-india-health-cohort-study-to-develop-personalized-disease-risk-predictions 2025-07-17T01:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/54c5226d13b159a9/22nd-century-group-expands-vln-reduced-nicotine-cigarette-partnerships-ahead-of-fda-mandate 2025-07-17T01:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/3a4cd99b61bd9c73/overture-orthopaedics-launches-overtureti-knee-resurfacing-system-for-early-osteoarthritis-treatment 2025-07-17T01:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/a95059ada81fa5df/idt-launches-hdr-enhancer-protein-to-boost-crispr-gene-editing-efficiency-in-therapeutic-applications 2025-07-17T01:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/470562dd5735ae2d/nexgel-expands-stada-partnership-with-1-million-investment-for-digestive-enzyme-and-scar-treatment-products 2025-07-17T01:16:29+00:00 hourly 0.9 https://trial.medpath.com/news/941baa6550a6492f/cms-proposes-new-payment-structure-for-skin-substitutes-regenerative-medicine-companies-welcome-reform 2025-07-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6032dde53640a257/dogs-demonstrate-high-accuracy-in-detecting-parkinson-s-disease-through-scent-analysis 2025-07-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d7670c05893530c/wehi-partners-with-parkinson-s-research-foundation-to-accelerate-drug-discovery-for-world-s-fastest-growing-neurological-condition 2025-07-16T23:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/1719a29b4c7a81f6/endtb-q-trial-reveals-need-for-personalized-treatment-in-drug-resistant-tuberculosis 2025-07-16T21:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/65921ae02644d850/cepi-awards-5-million-to-nagasaki-university-for-ai-powered-nanoball-mrna-vaccine-platform-against-disease-x 2025-07-16T21:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/4abab8289b7fe44d/neocast-liquid-embolic-shows-promise-for-pain-free-treatment-of-chronic-subdural-hematoma 2025-07-16T21:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/3629c73074d4c863/federal-circuit-invalidates-shockwave-medical-s-intravascular-lithotripsy-patent-in-precedential-ruling 2025-07-16T21:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/6e30a8e971c31a9d/okyo-pharma-secures-1-9m-non-dilutive-funding-following-positive-phase-2-results-and-fda-fast-track-designation 2025-07-16T21:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/ef595981ee8cf536/astrazeneca-partners-with-cspc-for-ai-driven-drug-discovery-platform-to-develop-novel-oral-therapies 2025-07-16T21:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/02e23f830128b180/regeneron-and-intellia-advance-crispr-gene-therapy-trial-for-hemophilia-b-treatment 2025-07-16T21:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/5fefd4161b405d5a/quetzal-therapeutics-launches-with-50-million-to-advance-oral-arsenic-trioxide-therapy-for-acute-promyelocytic-leukemia 2025-07-16T21:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/b86f62cf22945eeb/msbai-secures-2m-dod-phase-iii-contract-for-guru-generation-2-ai-platform 2025-07-16T21:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/627e9494eabfeaaa/fda-reviewers-flag-discordant-results-for-rexulti-sertraline-ptsd-treatment-ahead-of-advisory-committee-meeting 2025-07-16T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/662bdc3717ea9e64/thermo-fisher-scientific-acquires-sanofi-s-new-jersey-manufacturing-site-to-expand-u-s-sterile-drug-production 2025-07-16T17:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/7921747a1721a4fd/polypid-unveils-60-day-glp-1-delivery-platform-to-transform-diabetes-and-weight-management-treatment 2025-07-16T17:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/24ca327a5a7e36b4/qualigen-therapeutics-secures-global-patent-protection-for-cancer-drug-qn-302-across-25-countries 2025-07-16T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/4e8ff4a920853290/miplyffa-shows-5-year-sustained-efficacy-in-rare-npc-disease-extension-study 2025-07-16T17:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/72b133d1f1a18e8e/voyager-therapeutics-advances-novel-apoe4-gene-therapy-for-alzheimer-s-disease-using-iv-delivered-tracer-platform 2025-07-16T17:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/5f2e7911acd980ca/cystic-fibrosis-foundation-commits-additional-24-million-to-prime-medicine-for-gene-editing-therapy-development 2025-07-16T17:28:43+00:00 hourly 0.9 https://trial.medpath.com/news/4f686087b3cae5a1/genetic-leap-receives-fda-ind-clearance-for-first-in-class-oral-il-2-modulator-gl-il2-138 2025-07-16T17:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/2c8dc81b87f6f1c0/cue-101-combination-therapy-achieves-50-response-rate-in-hpv-head-and-neck-cancer-trial 2025-07-16T17:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/460580a1d3ed0463/johnson-johnson-raises-2025-outlook-as-oncology-portfolio-drives-24-growth 2025-07-16T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/ce54b20f8e4c6895/fda-reviewers-question-efficacy-of-otsuka-s-brexpiprazole-zoloft-combination-for-ptsd-treatment 2025-07-16T17:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/cdb91f5f62e91897/endeavor-biomedicines-receives-dual-orphan-drug-designation-for-taladegib-in-idiopathic-pulmonary-fibrosis 2025-07-16T17:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/00d711a8a6c7a493/logicare3pl-secures-exclusive-distribution-partnership-for-chirhostim-diagnostic-product 2025-07-16T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/62a690ea8f6ff09c/stargardt-disease-pipeline-shows-promising-progress-with-multiple-gene-therapies-advancing-to-late-stage-trials 2025-07-16T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/84aa5c96c19a9f50/fda-accepts-biosimilar-application-for-bat2506-proposed-golimumab-alternative 2025-07-16T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/0f48acefb0a8c5cf/sandboxaq-and-ioncologi-partner-to-develop-ai-driven-mrna-vaccine-for-glioblastoma 2025-07-16T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/ef941e94c6079718/tempus-ai-receives-fda-510-k-clearance-for-ecg-low-ef-software-to-detect-heart-failure-risk 2025-07-16T17:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/b1654a371db9cb3b/piccolo-medical-receives-fda-clearance-for-next-generation-smartpicc-technology 2025-07-16T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/405b6352bc143014/university-of-cincinnati-launches-phase-2-trial-of-novel-endocannabinoid-enhancing-drug-for-multiple-sclerosis-spasticity 2025-07-16T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/07b714d10f68c634/medtronic-initiates-pele-clinical-trial-for-onyx-liquid-embolic-system-in-peripheral-arterial-hemorrhage 2025-07-16T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/f35e3b60e3b13053/msc-derived-extracellular-vesicles-show-promise-as-cell-free-therapeutics-across-multiple-disease-areas 2025-07-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b1b5ef655461a698/cms-launches-multi-state-payment-model-to-expand-access-to-sickle-cell-gene-therapies 2025-07-16T13:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/86f463b8c61941e9/sprim-pro-and-obviohealth-expand-partnership-to-accelerate-digital-clinical-trial-innovation 2025-07-16T13:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/89d5f4a0a242577b/ibi343-shows-promising-efficacy-in-cldn18-2-positive-gastric-cancer-with-improved-safety-profile 2025-07-16T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/b1b38433facbe498/australian-companies-form-strategic-alliance-to-boost-advanced-therapy-manufacturing-capacity 2025-07-16T13:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/52c99d3764efa2e0/uk-digital-health-platform-numan-raises-60m-to-expand-into-women-s-health 2025-07-16T13:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/2b2a4776ce0fd213/atricure-completes-enrollment-in-landmark-6500-patient-leaaps-trial-for-stroke-prevention 2025-07-16T13:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/24210c14c9f98bfb/sino-biopharm-acquires-lanova-medicines-for-950m-expanding-innovative-drug-pipeline 2025-07-16T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/6b279b89e55bd41f/stelara-biosimilars-capture-market-share-as-j-j-s-blockbuster-drug-faces-33-7-sales-decline 2025-07-16T13:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/6b12eab8f1caacf4/ps17-9-million-wellcome-grant-funds-major-initiative-to-combat-deadly-fungal-infections 2025-07-16T13:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/79b0f699e888d5af/apple-airpods-pro-2-receive-fda-clearance-as-over-the-counter-hearing-aids 2025-07-16T13:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/ec8cd06eaac828e7/sanofi-s-sar446597-gene-therapy-receives-fda-fast-track-designation-for-geographic-atrophy-treatment 2025-07-16T13:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/2564f062feb33fb5/icon-leads-phase-1-clinical-trial-performance-with-highest-sponsor-satisfaction-score 2025-07-16T13:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/0dbff8e80f299a60/ai-powered-diabetic-retinopathy-screening-achieves-99-accuracy-and-expands-to-pharmacy-networks 2025-07-16T10:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/c88537c982a4d206/nci-initiates-4-8-million-clinical-trial-of-senhwa-s-first-in-class-cancer-drug-cx-5461 2025-07-16T09:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/3a32ef197899bb69/4moving-biotech-initiates-phase-2a-trial-of-first-in-class-glp-1-therapy-for-knee-osteoarthritis 2025-07-16T09:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/5da7363f7f5cf600/astrazeneca-s-anselamimab-fails-primary-endpoint-in-phase-iii-al-amyloidosis-trial-shows-promise-in-patient-subgroup 2025-07-16T09:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/aa5a4b669e53df30/phase-scientific-secures-exclusive-u-s-distribution-rights-for-febridx-rapid-respiratory-infection-test 2025-07-16T09:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/b9d6bb881e1d9e6c/pragmatic-clinical-trials-bridge-gap-between-research-and-real-world-healthcare-practice 2025-07-16T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/98b83a2d421bea3f/mcmaster-study-identifies-most-effective-treatments-for-chronic-hives-through-comprehensive-meta-analysis 2025-07-16T05:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/680216ab8140e253/fda-issues-warning-letters-to-seven-companies-marketing-illegal-opioid-alternative-products-containing-7-hydroxymitragynine 2025-07-16T05:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/69f922f0edcf469e/who-includes-arkbio-s-ziresovir-in-pediatric-rsv-drug-priority-list-marking-first-chinese-anti-rsv-drug-recognition 2025-07-16T05:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/a397e8af7c28cb02/btx-a51-shows-promise-in-relapsed-refractory-aml-with-notable-activity-in-runx1-mutated-patients 2025-07-16T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c57abf149dbcbf1/expert-calls-for-standardized-reflexive-biomarker-testing-to-address-treatment-delays-in-lung-cancer 2025-07-16T02:55:55+00:00 hourly 0.9 https://trial.medpath.com/news/a1737bc95dc3b487/immorta-bio-advances-senolytic-immunotherapy-senovax-toward-phase-i-iia-trial-in-advanced-nsclc 2025-07-16T01:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/daf8dcd761c78748/aptar-pharma-acquires-mod3-pharma-s-clinical-trial-manufacturing-capabilities-to-strengthen-early-phase-drug-development-services 2025-07-16T01:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/f22a6f74d7a7fb9f/repare-therapeutics-licenses-pkmyt1-inhibitor-lunresertib-to-debiopharm-in-267m-deal 2025-07-16T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/9d160dca0d6935af/compremium-launches-first-in-human-study-of-non-invasive-thyroid-cancer-diagnostic-device 2025-07-16T01:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/960228abb3e0bce4/fda-issues-warning-letter-to-whoop-over-unapproved-blood-pressure-feature 2025-07-16T01:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/2baf4fa83f1d5bfb/omniscope-pioneers-immune-profiling-breakthrough-for-personalized-pediatric-cancer-therapy 2025-07-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd736a8ce354f30c/fda-advisory-panel-votes-against-gsk-s-blenrep-for-multiple-myeloma-over-eye-safety-concerns 2025-07-15T21:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/20904303ff4625bd/csl-consolidates-r-d-operations-to-six-global-hubs-in-strategic-shift-toward-external-partnerships 2025-07-15T21:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/ae523831889371ca/celcuity-secures-patent-extension-for-gedatolisib-through-2042-strengthening-breast-cancer-drug-portfolio 2025-07-15T21:23:10+00:00 hourly 0.9 https://trial.medpath.com/news/43c394b9baea9aab/bioaffinity-technologies-secures-international-patents-for-cypath-lung-cancer-diagnostic-in-china-and-canada 2025-07-15T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/0b1e4f6ad9941de9/brazilian-pharmaceutical-industry-faces-patent-suspension-threat-amid-u-s-trade-tensions 2025-07-15T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/6d15767febfc5faf/sun-pharma-s-halol-plant-fails-another-fda-inspection-over-contamination-concerns 2025-07-15T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/457c45e5c8395ede/fda-raises-eye-safety-concerns-for-gsk-s-blenrep-ahead-of-advisory-committee-review 2025-07-15T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/a6c55756351de318/egetis-therapeutics-advances-toward-us-nda-submission-for-tiratricol-following-fda-breakthrough-therapy-designation 2025-07-15T21:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/f170a28f7a971a44/evestia-clinical-merges-with-atlantic-research-group-to-create-global-specialist-cro 2025-07-15T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/da918ce32feab920/taxis-pharmaceuticals-receives-fda-qidp-designation-for-txa14007-efflux-pump-inhibitor-to-combat-antibiotic-resistant-pneumonia 2025-07-15T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/af7daae5504c412c/fda-approves-kirsty-as-first-interchangeable-rapid-acting-insulin-aspart-biosimilar 2025-07-15T21:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/7e90fcf43b8716b9/psilocybin-shows-anti-aging-properties-in-preclinical-study-extending-cellular-lifespan-by-50 2025-07-15T21:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/18c65e249d6db24a/aatec-medical-partners-with-northway-biotech-to-scale-atl-105-production-for-non-cf-bronchiectasis-treatment 2025-07-15T17:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/fbdad592616b720d/iovance-biotherapeutics-names-corleen-roche-as-cfo-during-commercial-launch-of-first-fda-approved-til-therapy 2025-07-15T17:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/5e17267d07792394/zydus-lifesciences-receives-fda-approval-for-generic-celecoxib-capsules-in-multiple-strengths 2025-07-15T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/f5b6cb0a8292e974/uc-davis-study-shows-stem-cell-therapy-enhances-immune-recovery-in-cats-with-coronavirus-offering-insights-for-long-covid-treatment 2025-07-15T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/5e91c3a729b60297/c-mo-medical-solutions-achieves-iso-13485-certification-for-ai-powered-cough-monitoring-technology 2025-07-15T17:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/f6c857d4471bd7ed/lisata-therapeutics-secures-composition-of-matter-patent-for-certepetide-through-2040 2025-07-15T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/8d043262ef262381/merakris-therapeutics-mtx-001-selected-as-finalist-for-advanced-wound-care-innovation-showcase 2025-07-15T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/166ac5d22a4f892b/sino-biopharmaceutical-acquires-lanova-medicines-for-951-million-targeting-pd-1xvegf-cancer-therapies 2025-07-15T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/a691f25871e8d346/medera-treats-first-patient-in-groundbreaking-gene-therapy-trial-for-duchenne-muscular-dystrophy-heart-failure 2025-07-15T17:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/d8c8cfc63610376f/tdm-guided-ustekinumab-optimization-shows-superior-long-term-efficacy-in-crohn-s-disease-maintenance-therapy 2025-07-15T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/f870af292920bafa/oncoc4-launches-adamunix-subsidiary-to-address-anti-drug-antibody-challenges-in-protein-therapeutics 2025-07-15T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/c7f9a448407f8612/elix-and-linc-launch-world-s-first-commercial-ai-drug-discovery-platform-using-federated-learning-from-16-pharmaceutical-companies 2025-07-15T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/949b6943d065b7ae/365mc-partners-with-raziel-therapeutics-to-advance-rzl-012-injectable-fat-reduction-treatment-in-south-korea 2025-07-15T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/a91c7df002827eaf/stem-cell-therapy-enables-kidney-transplant-patients-to-live-drug-free-for-over-two-years 2025-07-15T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/fab05de433b4cb6a/hengrui-and-kailera-s-dual-glp-1-gip-obesity-drug-achieves-18-weight-loss-in-phase-3-trial 2025-07-15T17:23:02+00:00 hourly 0.9 https://trial.medpath.com/news/0ba96294696cf3ba/fred-hutch-launches-national-vanguard-study-to-evaluate-multi-cancer-detection-blood-tests 2025-07-15T17:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9b5a06c0e37cd88/fda-grants-orphan-drug-designation-to-sh-110-oral-liquid-therapy-for-glioma-treatment 2025-07-15T17:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/9aebae46554ec29d/machine-learning-models-achieve-perfect-accuracy-in-early-childhood-diabetes-prediction-using-gene-expression-biomarkers 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e37c0dd71c601b39/advanced-antibacterial-implant-materials-show-promise-against-bone-infections 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/028c4ecba4216af0/gut-microbiota-emerges-as-key-therapeutic-target-for-osteoporosis-through-novel-gut-bone-axis 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/54d1088a7043fdcb/researchers-identify-stromal-immunosuppressive-barrier-in-gastric-cancer-that-drives-treatment-resistance 2025-07-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cda4c41e9f89fec2/menin-inhibitors-market-poised-for-strong-growth-as-revuforj-becomes-first-fda-approved-drug-in-class 2025-07-15T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c5f4755dc559b03/large-scale-danish-study-finds-no-link-between-aluminum-in-childhood-vaccines-and-chronic-diseases 2025-07-15T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/2e06ddf26d65fb24/quidelortho-and-buhlmann-launch-rapid-gastrointestinal-biomarker-assays-for-ibd-and-pancreatic-insufficiency-diagnosis 2025-07-15T13:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/cd0a3b5234bb0561/us-maternal-mortality-crisis-deepens-as-deaths-nearly-double-during-pandemic-commonwealth-fund-analysis-reveals 2025-07-15T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/146bb1537799563e/acumen-pharmaceuticals-partners-with-jcr-to-develop-enhanced-brain-delivery-therapy-for-alzheimer-s-disease 2025-07-15T13:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/58887cc93ed41bf7/4teen4-s-procizumab-shows-first-in-human-evidence-of-shock-reversal-in-terminally-ill-patients 2025-07-15T13:22:32+00:00 hourly 0.9 https://trial.medpath.com/news/985b8959c726a78a/oncomatryx-secures-eur12-5-million-eic-accelerator-funding-to-advance-novel-adc-platform-for-hard-to-treat-cancers 2025-07-15T13:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/d78fb1e2a054c7b7/follicular-lymphoma-market-poised-for-6-cagr-growth-through-2034-as-novel-therapies-advance 2025-07-15T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/1074da40a94d953c/bridge-to-hope-trial-shows-hope-reduces-liver-transplant-costs-by-28565-and-severe-rejection-rates 2025-07-15T12:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/aaa7fb92ce2aad1f/hiv-treatment-pipeline-advances-with-extended-release-formulations-from-weekly-to-annual-dosing 2025-07-15T09:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/ed4d4b1b37d75f2e/korean-researchers-develop-precision-nanobody-therapy-for-lung-adenocarcinoma-with-90-tumor-reduction 2025-07-15T09:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/b4366820e349c671/oxford-biodynamics-episwitch-biomarkers-show-promise-in-pfizer-bladder-cancer-trial 2025-07-15T09:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/8a51911845374c96/synendos-therapeutics-names-dr-george-garibaldi-as-cmo-to-lead-phase-2-development-of-novel-neuropsychiatric-therapy 2025-07-15T09:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/29d35822c7bf5069/mit-and-ucsb-researchers-develop-light-activated-platform-to-discover-broad-spectrum-antiviral-compounds 2025-07-15T09:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/2d94bc0600caf015/biophytis-partners-with-lynx-analytics-to-accelerate-ai-driven-drug-discovery-for-sarcopenia 2025-07-15T09:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/56e4c92663ff2a6e/usaid-funding-cuts-could-trigger-14-million-deaths-and-devastating-tb-crisis-by-2030 2025-07-15T08:54:05+00:00 hourly 0.9 https://trial.medpath.com/news/96002d5cf0cecd5b/heart-failure-pipeline-shows-strong-growth-with-75-therapies-in-development-across-70-companies 2025-07-15T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/e60b2857095ac14b/avacopan-demonstrates-superior-safety-profile-in-anca-associated-vasculitis-across-multiple-clinical-trials 2025-07-15T06:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f570eea12d68fa7/india-s-nppa-sets-retail-prices-for-71-essential-drug-formulations-including-cancer-and-diabetes-medications 2025-07-15T05:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/c698d425c0a32101/fda-approves-updated-irrigation-rate-for-johnson-johnson-s-varipulse-pulsed-field-ablation-platform 2025-07-15T05:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/c359d10f27053b7c/molecular-profiling-transforms-aml-treatment-strategy-as-mrd-testing-guides-transplant-decisions 2025-07-15T05:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/ce5c0354ffde0783/telemedicine-transforms-oncology-care-with-86-of-cancer-specialists-calling-virtual-visits-essential 2025-07-15T03:54:52+00:00 hourly 0.9 https://trial.medpath.com/news/18b63c2f57eed2db/oncology-pharmacists-lead-biosimilar-integration-strategies-to-optimize-cancer-care-access-and-costs 2025-07-15T02:54:57+00:00 hourly 0.9 https://trial.medpath.com/news/75bf96c948463ec6/anti-nausea-drug-aprepitant-shows-significant-survival-benefits-in-triple-negative-breast-cancer 2025-07-15T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/f2734a8c8b6575f0/nostrum-laboratories-recalls-sucralfate-tablets-following-bankruptcy-and-operational-shutdown 2025-07-15T01:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/3491ce3f417be406/60-degrees-pharmaceuticals-seeks-fda-mums-designation-for-first-oral-canine-babesiosis-treatment 2025-07-15T01:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/0495455e67cfbbe2/unibar-corporation-secures-european-patent-for-capsiclear-eye-health-ingredient-targeting-glaucoma-treatment 2025-07-15T01:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/f93daa89e8101fef/glp-1-receptor-agonists-naturally-restore-testosterone-levels-in-men-with-obesity-and-type-2-diabetes 2025-07-15T01:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/f65dc572836892d1/simulations-plus-invests-1-million-in-clinical-trial-technology-company-nurocor 2025-07-15T01:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/4dc0b277c3f0dc17/glp-1-weight-loss-drugs-remain-effective-despite-treatment-interruptions-when-combined-with-lifestyle-changes 2025-07-15T01:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/6522077a1344e773/head-to-head-trial-compares-risankizumab-and-vedolizumab-in-treatment-naive-ulcerative-colitis-patients 2025-07-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/931aabfe617ef62f/whoop-challenges-fda-classification-of-blood-pressure-monitoring-feature-as-medical-device 2025-07-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2692a085390ff652/bsa-encapsulated-morin-hydrate-nanoparticles-show-enhanced-anticancer-activity-against-colorectal-cancer 2025-07-14T21:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/86436789a3609c45/kaizen-biosciences-advances-pediatric-antibiotic-formulation-with-reduced-clavulanate-for-infants 2025-07-14T21:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/1151b101b65185df/turn-therapeutics-initiates-first-clinical-trial-of-topical-il-36-inhibitor-gx-03-for-moderate-to-severe-eczema 2025-07-14T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/1483419798aed962/neurosense-s-primec-shows-33-reduction-in-als-disease-progression-in-phase-2b-trial 2025-07-14T21:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/8d420c1bdb89dac5/uaeu-researcher-secures-four-patents-for-computational-drug-design-and-medical-device-innovations 2025-07-14T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/72a804bda78f2150/kenvue-ceo-thibaut-mongon-steps-down-as-consumer-health-company-undergoes-strategic-review 2025-07-14T17:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/3e806a496f502afc/dare-bioscience-reports-positive-interim-phase-3-results-for-ovaprene-hormone-free-monthly-contraceptive 2025-07-14T17:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/db5cf89dbac8040f/japanese-researchers-identify-gut-bacteria-strain-that-enhances-cancer-immunotherapy-effectiveness 2025-07-14T17:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/01b48f1e88f94bd3/avalon-globocare-secures-hong-kong-patent-for-bispecific-car-t-and-car-nk-cell-technology 2025-07-14T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/c31937639bcc88bb/health-canada-extends-evkeeza-approval-to-infants-as-young-as-6-months-for-rare-cholesterol-disorder 2025-07-14T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/840bea49c56e5d14/sonnet-biotherapeutics-pivots-to-cryptocurrency-with-888-million-hype-token-treasury-strategy 2025-07-14T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/37a1c2df3b8d8d10/sun-pharma-launches-deuruxolitinib-for-severe-alopecia-areata-in-us-market 2025-07-14T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/a6232b3d901f61b2/pci-pharma-services-secures-strategic-investment-to-expand-biotherapeutics-manufacturing-capabilities 2025-07-14T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/93855a728c987730/endometriosis-pain-treatment-pipeline-shows-mixed-results-as-nhs-approves-first-daily-oral-therapy 2025-07-14T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/71d66464b6b3ef53/uniquity-bio-appoints-will-kane-as-ceo-to-lead-anti-tslp-therapy-through-phase-iii-development 2025-07-14T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/2e312952c329ec65/relmada-therapeutics-abandons-depression-drug-esmethadone-after-three-failed-phase-iii-trials 2025-07-14T17:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/1de681b3307e5069/essa-pharma-agrees-to-1-91-per-share-acquisition-by-xenotherapeutics-in-wind-down-transaction 2025-07-14T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/ee96b163e311f46e/vivos-inc-submits-fda-application-for-radiogel-hydrogel-based-cancer-therapy 2025-07-14T17:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/f9b293f3e68d2ed2/viiv-healthcare-expands-generic-license-for-long-acting-hiv-treatment-to-133-countries 2025-07-14T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/64e1adcf927bc96b/indiana-university-receives-11-3-million-nih-grant-to-advance-ship1-inhibitor-for-alzheimer-s-disease 2025-07-14T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/0e1d5ed43216ff2e/waters-corporation-and-bd-announce-17-5-billion-merger-to-create-life-sciences-and-diagnostics-leader 2025-07-14T13:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/81bcd0c562ffbd4b/illimis-therapeutics-secures-42m-series-b-to-advance-gaia-platform-for-alzheimer-s-and-immune-disease-treatments 2025-07-14T13:19:20+00:00 hourly 0.9 https://trial.medpath.com/news/63b9fc5bc8f974ff/ascentage-pharma-raises-192m-in-oversubscribed-share-placement-to-advance-cancer-pipeline 2025-07-14T13:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/9f89a2147b2080e6/ztz-bio-secures-fourth-global-big-pharma-partnership-for-long-acting-injectable-drug-development 2025-07-14T08:57:31+00:00 hourly 0.9 https://trial.medpath.com/news/2efc32f52436a022/cures-within-reach-launches-100000-grant-program-for-ai-driven-drug-repurposing-clinical-trials 2025-07-14T08:57:27+00:00 hourly 0.9 https://trial.medpath.com/news/338257a3a75ad022/imugene-reports-75-response-rate-in-diffuse-large-b-cell-lymphoma-trial 2025-07-14T08:56:59+00:00 hourly 0.9 https://trial.medpath.com/news/40f1c5360427389e/antimalarial-drug-efficacy-remains-high-in-mozambique-and-liberia-despite-regional-resistance-concerns 2025-07-14T08:56:55+00:00 hourly 0.9 https://trial.medpath.com/news/9758c1aac529e6c0/imugene-s-azer-cel-achieves-75-response-rate-in-phase-1b-trial-for-relapsed-dlbcl 2025-07-14T04:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/6bfff02820c27422/carsgen-secures-european-patent-protection-for-gpc3-targeted-car-t-therapy-following-successful-defense-at-epo 2025-07-14T04:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/8dc2a698b3aa7f9b/uk-and-vietnam-strike-ps250-million-pharmaceutical-trade-deal-to-accelerate-medicine-registration 2025-07-14T04:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/82224d6c02b4a0d0/genomill-health-s-bridge-capture-technology-matches-gold-standard-sensitivity-for-liquid-biopsy-in-metastatic-colorectal-cancer 2025-07-14T03:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d896f5c3cec4d11/singapore-developed-cancer-drug-prl3-zumab-shows-promise-for-treating-vision-loss-in-amd-and-diabetic-retinopathy 2025-07-14T01:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/4e016728c979d9b0/implanted-vagus-nerve-stimulation-device-shows-promise-for-treatment-resistant-rheumatoid-arthritis 2025-07-13T21:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/0d906fccec62296f/100-orange-juice-shows-no-blood-sugar-impact-in-type-2-diabetes-patients-clinical-trial-reveals 2025-07-13T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/190b5f4e228c27ff/two-decades-of-nk-cell-trials-show-promise-for-aml-treatment-with-37-complete-remission-rate 2025-07-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c13409332b4d6c90/functional-nanomaterials-advance-photothermal-therapy-for-cancer-treatment 2025-07-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c82d66fb34c9158/pfizer-receives-cdsco-approval-for-phase-iii-rsv-vaccine-trial-in-india-with-conditional-requirements 2025-07-13T13:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/aa88be6d6d5ca375/cipla-plans-entry-into-india-s-weight-management-market-as-obesity-becomes-strategic-priority 2025-07-13T09:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/912fb1e3be8dc070/us-aid-cuts-halt-hiv-vaccine-research-in-south-africa-threatening-global-progress 2025-07-13T05:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/56ffb936912e59d5/intelligent-bio-solutions-validates-fingerprint-sweat-testing-for-drug-detection-with-pharmacokinetic-study-data 2025-07-13T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/95e5f4447456dcf7/elegen-and-nutcracker-therapeutics-launch-industry-s-first-fully-cell-free-manufacturing-platform-for-rna-based-personalized-cancer-therapeutics 2025-07-13T05:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/a3601061485c755f/regeneron-and-biontech-advance-phase-2-trial-combining-cancer-vaccine-bnt116-with-cemiplimab-for-advanced-nsclc 2025-07-13T01:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/0a59dadc88c6d811/ucla-researchers-receive-950000-grant-to-launch-multi-institutional-trial-of-zipalertinib-for-egfr-mutated-cancers 2025-07-13T01:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/382351ec511faf3d/ripretinib-shows-comparable-survival-to-sunitinib-in-advanced-gist-with-improved-safety-profile 2025-07-12T21:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/b15bdf237ae8ca6f/cel-sci-raises-5-7m-to-fund-pivotal-multikine-trial-for-head-and-neck-cancer 2025-07-12T21:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/7d37d2c0f41cb28c/profusa-goes-public-on-nasdaq-with-tissue-integrating-biosensor-platform-for-chronic-disease-management 2025-07-12T21:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/6efa304b378a1772/real-world-study-reveals-persistent-gaps-in-molecular-testing-and-targeted-therapy-implementation-for-aml-and-mds 2025-07-12T21:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/e004fee2106264f5/simbiosys-receives-third-fda-clearance-for-ai-powered-breast-cancer-surgery-platform-tumorsight-viz 2025-07-12T21:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/f66f78b90a65211e/cms-proposes-medicare-coverage-for-renal-denervation-devices-to-treat-uncontrolled-hypertension 2025-07-12T17:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/dc1f7f604844500e/indian-regulators-reject-troikaa-s-rapid-iv-paracetamol-bolus-over-safety-and-efficacy-concerns 2025-07-12T17:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/13bd4f0d27a4f6e7/anthem-biosciences-raises-rs-1016-crore-from-anchor-investors-ahead-of-rs-3395-crore-ipo 2025-07-12T17:19:47+00:00 hourly 0.9 https://trial.medpath.com/news/dc8c144cb7a29a89/regeneron-initiates-long-term-gene-modified-t-cell-therapy-safety-study 2025-07-12T17:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/78664c3aba96d687/photodynamic-therapy-shows-promise-in-cancer-treatment-with-global-market-expected-to-reach-6-billion-by-2030 2025-07-12T17:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/4ef7e019b66e2385/karyopharm-therapeutics-cuts-20-of-workforce-as-strategic-alternative-search-stalls 2025-07-12T13:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/ec66bf14b585a598/astrazeneca-initiates-real-world-study-of-koselugo-in-korean-patients-to-fulfill-post-approval-commitment 2025-07-12T13:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/10f5f5d10331786f/real-world-data-successfully-integrated-as-external-control-arm-in-her2-breast-cancer-trial 2025-07-12T13:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/427265be43b82301/fda-rejects-ultragenyx-gene-therapy-for-sanfilippo-syndrome-over-manufacturing-concerns 2025-07-12T09:20:22+00:00 hourly 0.9 https://trial.medpath.com/news/6e0f1b6be3496a48/simris-group-adc-partnership-falls-through-as-eu-partner-withdraws-following-strategic-review 2025-07-12T09:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/f9c0ce2188724d08/mink-therapeutics-achieves-complete-cancer-remission-with-off-the-shelf-inkt-cell-therapy 2025-07-12T09:17:05+00:00 hourly 0.9 https://trial.medpath.com/news/72bbe429c8e01863/gabapentin-linked-to-increased-dementia-risk-in-chronic-pain-patients 2025-07-12T09:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/b01810a11a476b0e/darolutamide-gains-fda-approval-for-metastatic-hormone-sensitive-prostate-cancer-following-aranote-trial-success 2025-07-12T09:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/769f324d0a29dcb4/independent-pharmacy-owner-develops-structured-career-advancement-model-for-pharmacy-technicians 2025-07-12T09:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/58db3917a4183c9a/targeted-therapies-transform-biliary-tract-cancer-treatment-landscape-with-fgfr2-inhibitors-leading-clinical-advances 2025-07-12T09:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/8ea3ad61878e573f/fda-issues-complete-response-letter-for-ultragenyx-s-ux111-gene-therapy-for-sanfilippo-syndrome-type-a 2025-07-12T09:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/69c67433319bdd98/early-molecular-milestones-critical-for-treatment-free-remission-success-in-chronic-myeloid-leukemia 2025-07-12T09:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/3471b752bf79a995/real-world-data-confirm-ivosidenib-efficacy-in-idh1-mutated-cholangiocarcinoma 2025-07-12T09:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/267cca745f261656/global-biotechnology-market-projected-to-reach-5-71-trillion-by-2034-driven-by-ai-powered-drug-discovery-and-tissue-engineering 2025-07-12T02:56:31+00:00 hourly 0.9 https://trial.medpath.com/news/89b71588beb72cee/mckesson-health-mart-expands-clinical-services-strategy-with-focus-on-chronic-care-management-and-pharmacogenomics 2025-07-12T02:55:17+00:00 hourly 0.9 https://trial.medpath.com/news/2516a53428c47f6e/nontargeted-hcv-screening-in-emergency-departments-identifies-34-more-new-infections-than-risk-based-approach 2025-07-12T02:54:19+00:00 hourly 0.9 https://trial.medpath.com/news/2c31e4d9a35da1a1/clinical-trial-system-faces-sustainability-crisis-as-costs-soar-and-workforce-shrinks 2025-07-12T02:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/ed59c46083ffe19d/mckesson-launches-micro-access-pharmacy-initiative-to-combat-pharmacy-deserts-in-underserved-communities 2025-07-11T21:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/818d1d469a5943c5/variational-ai-partners-with-merck-in-349-million-ai-drug-discovery-collaboration 2025-07-11T20:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/f2e24879f4212c88/uk-phase-iii-trial-shows-low-risk-thyroid-cancer-patients-can-safely-skip-radioiodine-ablation-after-surgery 2025-07-11T20:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/fc1b09e351531f13/ema-lifts-age-restriction-on-valneva-s-chikungunya-vaccine-after-safety-review 2025-07-11T20:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/53cac70da2685abb/wockhardt-exits-us-generics-business-to-focus-on-novel-antibiotic-drug-discovery 2025-07-11T20:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/c936e9dd130b8a9c/onco-innovations-appoints-dr-islam-mohamed-as-scientific-advisory-board-chair-to-advance-oncology-pipeline 2025-07-11T20:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/7f7f0a50fb866bf0/novel-non-viral-car-t-therapy-ap8901-enters-phase-i-trial-for-ephb4-positive-solid-tumors 2025-07-11T16:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/8379b508b54eb21a/dare-bioscience-receives-6-million-grant-installment-for-smart-drug-delivery-platform-development 2025-07-11T16:59:42+00:00 hourly 0.9 https://trial.medpath.com/news/681cd733fdb503d5/microsoft-launches-bioemu-ai-system-to-accelerate-drug-discovery-through-protein-simulation 2025-07-11T16:57:14+00:00 hourly 0.9 https://trial.medpath.com/news/7b44196aeb6a582e/brenig-therapeutics-appoints-new-leadership-and-expands-parkinson-s-disease-pipeline-with-nlrp3-inhibitor-acquisition 2025-07-11T16:56:26+00:00 hourly 0.9 https://trial.medpath.com/news/96c7b650dd82d8b5/scalp-cooling-combined-with-antioxidants-shows-promise-for-preventing-chemotherapy-induced-hair-loss 2025-07-11T16:55:58+00:00 hourly 0.9 https://trial.medpath.com/news/8540c182191bfe0d/intuitive-receives-fda-clearance-for-vessel-sealer-curved-first-advanced-energy-instrument-approved-for-lymphatic-vessel-transection 2025-07-11T16:55:46+00:00 hourly 0.9 https://trial.medpath.com/news/88ff2f25aa750316/precigen-stock-surges-48-84-following-positive-fda-designations-for-gene-therapy-pipeline 2025-07-11T15:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/db7544c46bc2a172/biologic-therapies-show-favorable-cancer-safety-profile-in-psoriatic-disease-patients 2025-07-11T14:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/ffbec1d4a21987bc/mink-therapeutics-reports-complete-remission-in-metastatic-testicular-cancer-patient-using-allogeneic-inkt-cell-therapy 2025-07-11T14:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/b81cd0728c369e03/cerevance-reports-positive-phase-1-results-for-novel-kcnk13-inhibitor-cvn293-targeting-neuroinflammation 2025-07-11T13:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/36368ab32e2869e5/i-peace-and-vita-therapeutics-partner-to-develop-universal-ips-cells-for-fshd-treatment 2025-07-11T13:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/46b0092dcb3e7bd7/fda-issues-class-ii-risk-warning-for-ritz-peanut-butter-crackers-due-to-mislabeling-that-could-trigger-life-threatening-allergic-reactions 2025-07-11T13:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/f63ec05f1839ab2e/rfk-jr-considers-dismantling-u-s-preventive-services-task-force-raising-healthcare-access-concerns 2025-07-11T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/b469e9d434de3041/sequoia-trial-data-reveals-sustained-responses-with-zanubrutinib-in-high-risk-cll-patients 2025-07-11T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c918d0862fadfa57/wacker-opens-new-biotechnology-center-in-munich-to-accelerate-biopharmaceutical-research 2025-07-11T11:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/b5ac73cfb5ea95c5/vsy-biotechnology-s-sinusoidal-trifocal-iol-technology-receives-japanese-approval 2025-07-11T11:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/655acbe39cc24ac6/australian-first-seek-and-destroy-cancer-therapy-begins-human-trials-targeting-cdcp1-protein 2025-07-11T10:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/c4e0d122df3b4ec3/fda-approved-parp-inhibitor-shows-80-tumor-reduction-in-ebv-driven-lymphoma 2025-07-11T10:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/96cc84f78c3b0230/wireless-nfc-implant-delivers-chemotherapy-deep-into-tumors-with-four-fold-improved-efficiency 2025-07-11T10:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/ad0eb95b4fca8400/australian-scientists-develop-real-time-ultrasound-imaging-system-to-enhance-brain-drug-delivery 2025-07-11T09:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/f8482f8ad37bfb6e/solvonis-therapeutics-raises-ps1m-to-accelerate-ai-driven-cns-drug-discovery-for-depression-and-stimulant-addiction 2025-07-11T09:18:48+00:00 hourly 0.9 https://trial.medpath.com/news/c6bd7e30c00f714b/mrna-victoria-funds-breakthrough-alzheimer-s-research-projects-targeting-prevention-and-treatment 2025-07-11T09:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/4e561d74350cbf64/targeted-protein-degradation-emerges-as-multi-billion-dollar-therapeutic-frontier-with-first-protac-approval-expected-in-2026 2025-07-11T08:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/ec24b4ebfd0e6780/brecadd-chemotherapy-preserves-fertility-better-than-standard-treatment-in-advanced-hodgkin-s-lymphoma 2025-07-11T08:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/20faf83e202a3c0b/hydrogels-emerge-as-next-generation-platform-for-precision-cancer-drug-delivery 2025-07-11T08:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/a7cbe46b3e0af862/bbot-completes-382-million-spac-merger-to-advance-next-generation-ras-targeted-cancer-therapeutics 2025-07-11T07:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/0a1ee4053d1b9faf/onetouch-pat-breast-imaging-system-demonstrates-promise-in-early-clinical-tests-with-ai-enhanced-detection 2025-07-11T06:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/ac57eb7f720b89e7/biogen-and-acumen-advance-alzheimer-s-research-with-long-term-data-and-novel-targeting-approaches-at-aaic-2025 2025-07-11T05:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/6e3089cccc2c5e26/compass-therapeutics-receives-fda-fast-track-designation-for-ctx-009-bispecific-antibody 2025-07-11T05:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/9f9f13a948627ac9/cdsco-mandates-online-submission-for-cell-and-gene-therapy-clinical-trial-applications 2025-07-11T05:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/ef23256ac051797f/hku-launches-gene-therapy-clinical-trial-for-chronic-hepatitis-b-cure 2025-07-11T05:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/35e8ca7a31da8102/lodestar-study-marks-first-tumor-agnostic-trial-of-parp-inhibitor-rucaparib-in-hrr-gene-variants 2025-07-11T04:19:33+00:00 hourly 0.9 https://trial.medpath.com/news/6aaaec9077ecfb28/tocogaia-tocotrienol-beverage-shows-anti-aging-benefits-in-six-month-clinical-trial 2025-07-11T04:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/941f4a17300bcb52/arvinas-ceo-john-houston-announces-retirement-following-protac-breakthrough-success 2025-07-11T04:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/179bf2be1c97ca3b/fda-approves-retifanlimab-plus-carboplatin-paclitaxel-for-advanced-anal-cancer-following-podium-303-trial-success 2025-07-11T03:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/1bd1e2eee0a563fd/mrna-technology-expands-beyond-covid-vaccines-into-cancer-and-rare-disease-therapeutics 2025-07-11T03:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/748471ecc1ebbe11/soleno-therapeutics-raises-200-million-to-fund-commercialization-of-first-fda-approved-prader-willi-syndrome-therapy 2025-07-11T02:21:54+00:00 hourly 0.9 https://trial.medpath.com/news/de5e7d12478138e6/careone-concierge-launches-clinical-study-for-fda-breakthrough-alzheimer-s-device 2025-07-11T02:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/d8ebedce186b4803/comprehensive-genomic-profiling-emerges-as-essential-standard-for-personalized-cancer-treatment 2025-07-11T02:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/e07f944f3212875f/global-oncology-cell-therapy-market-projected-to-reach-25-billion-by-2031 2025-07-11T02:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/a4e4894f24f746b9/nalirifox-emerges-as-effective-alternative-to-folfirinox-in-metastatic-pancreatic-cancer-treatment 2025-07-11T02:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/45a6b1cf734a0e33/chromophobe-renal-cell-carcinoma-shows-immune-cold-environment-and-poor-response-to-checkpoint-inhibitors 2025-07-11T02:17:37+00:00 hourly 0.9 https://trial.medpath.com/news/aa7902517c38bc6e/bristol-myers-squibb-advances-two-multiple-myeloma-trials-with-novel-drug-combinations 2025-07-11T01:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/15fc59e6b5eb58d6/anti-gpc3-targeted-therapies-market-expands-with-novel-treatment-approaches-for-hepatocellular-carcinoma 2025-07-11T01:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/dd7d302e9fe59670/broken-string-biosciences-and-biolizard-partner-to-develop-ai-powered-safeguide-for-crispr-gene-editing-safety 2025-07-11T00:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/754e091599adc410/ultragenyx-s-setrusumab-phase-3-trial-continues-after-interim-analysis-fails-to-meet-early-termination-threshold 2025-07-11T00:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/2c131593d5690a92/iovance-biotherapeutics-recruits-former-fda-oncology-leader-marc-theoret-as-senior-vp-of-regulatory-strategy 2025-07-11T00:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/be91bea85b5ce8bb/fda-approves-first-year-long-flea-and-tick-injectable-for-dogs 2025-07-11T00:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/e1e774ace20182b8/creative-medical-technology-secures-patent-protection-for-immcelz-cell-therapy-platform-across-heart-failure-and-type-1-diabetes 2025-07-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd74825236d08c61/synchrony-medical-receives-fda-510-k-clearance-for-libairty-airway-clearance-system 2025-07-10T23:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/d0c136c1c7409038/cognition-therapeutics-receives-fda-endorsement-for-alzheimer-s-drug-zervimesine-phase-3-trial-design 2025-07-10T22:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/f7fa6db86e0868ee/genmab-and-biontech-advance-two-phase-1-2-cancer-trials-testing-novel-antibody-therapies 2025-07-10T22:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/29319b42f996dc05/inventiva-appoints-new-leadership-team-to-advance-mash-drug-lanifibranor-through-phase-3-trial 2025-07-10T22:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/3d962473555e4ede/aqtual-raises-31-million-to-advance-novel-cfdna-platform-for-rheumatoid-arthritis-therapy-prediction 2025-07-10T21:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/b343182f5d81f39f/xylocor-therapeutics-initiates-phase-2b-trial-for-gene-therapy-xc001-in-refractory-angina 2025-07-10T21:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/af59382344f25f90/quince-therapeutics-strengthens-scientific-advisory-board-with-leading-immunologist-ahead-of-phase-3-results 2025-07-10T21:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/0f01a858f9551420/federal-circuit-reverses-ptab-decision-on-brimonidine-eye-redness-patent-in-landmark-claim-construction-ruling 2025-07-10T21:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/7a3c8725d4a3016c/five-new-york-cancer-centers-form-empire-state-cellular-therapy-consortium-to-accelerate-cell-and-gene-therapy-development 2025-07-10T21:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/6e43dfc16fe0d072/ut-southwestern-scientists-develop-targeted-gene-therapy-for-alpha-1-antitrypsin-deficiency-using-designer-lipid-nanoparticles 2025-07-10T21:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/5f323615e6eac960/cannabinoid-drug-development-accelerates-with-50-companies-advancing-clinical-trials 2025-07-10T21:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/7bdb6f61dafb3698/novartis-secures-canadian-public-reimbursement-for-cosentyx-in-hidradenitis-suppurativa 2025-07-10T21:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/89425aaf2932617e/astrazeneca-conducts-real-world-safety-study-for-anticoagulation-reversal-agent-ondexxya 2025-07-10T21:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/49fd797644baa8b9/alvotech-appoints-linda-jonsdottir-as-chief-financial-officer 2025-07-10T21:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/5f42587015a49765/baseline-steroid-use-significantly-reduces-immune-checkpoint-inhibitor-effectiveness-in-nsclc-patients 2025-07-10T21:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/73879bbc6912c44f/pelthos-therapeutics-launches-zelsuvmi-first-fda-approved-at-home-treatment-for-molluscum-contagiosum 2025-07-10T20:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/c7f68e91635d5c3d/dymicron-s-diamond-based-cervical-disc-receives-fda-approval-to-begin-u-s-clinical-trial 2025-07-10T20:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/73ebf7276cbfc3fa/real-world-evidence-validates-amivantamab-lazertinib-combination-in-advanced-nsclc-treatment 2025-07-10T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/42aa756988eb147d/modified-neovax-cancer-vaccine-shows-enhanced-immune-response-in-melanoma-patients 2025-07-10T20:15:05+00:00 hourly 0.9 https://trial.medpath.com/news/8e6bf15c73f02c07/il-2-inhibitor-pipeline-expands-with-20-companies-developing-22-therapeutic-candidates 2025-07-10T20:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/ed73705cdad96728/sernova-and-eledon-partner-to-advance-type-1-diabetes-bio-hybrid-organ-therapy-with-novel-immunosuppression 2025-07-10T20:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/6f92db46a4377475/eolas-therapeutics-assumes-full-development-rights-to-first-in-class-orexin-1-receptor-antagonist-azd4041-for-substance-use-disorders 2025-07-10T18:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/6cf0d75120395453/niagen-bioscience-secures-exclusive-license-for-nicotinamide-riboside-as-parkinson-s-disease-therapy 2025-07-10T18:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/0e2cf9927cf87a88/university-of-cincinnati-joins-international-phase-1-trial-testing-car-t-cell-therapy-for-multiple-sclerosis 2025-07-10T16:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/8d51a5c31ba690be/jazz-pharmaceuticals-names-renee-gala-as-ceo-in-strategic-leadership-transition 2025-07-10T16:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/9ce7d6b55d30b58c/fda-grants-breakthrough-therapy-designation-to-tsnd-201-for-ptsd-treatment 2025-07-10T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/ad4766e1e32606c9/genmab-advances-two-phase-3-and-phase-2-trials-testing-acasunlimab-combinations-in-lung-cancer-and-melanoma 2025-07-10T16:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/b17c9faf9876fdff/fifty1-ai-labs-completes-landmark-phase-iii-revive-trial-for-long-covid-treatment 2025-07-10T16:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/3d3a69abe1ae92dc/painreform-expands-into-ophthalmology-with-3m-strategic-investment-in-layerbio-s-ocuring-k 2025-07-10T16:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/65205ea874c4ed8e/zorevunersen-shows-promising-cognitive-and-behavioral-improvements-in-dravet-syndrome-phase-3-trial-analysis 2025-07-10T16:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/49b453a8f0274d55/sk-capital-enters-exclusive-talks-to-acquire-lisi-medical-in-eur179m-medtech-cdmo-deal 2025-07-10T16:29:39+00:00 hourly 0.9 https://trial.medpath.com/news/d8c86549e9195c19/fda-publishes-over-200-drug-rejection-letters-in-historic-transparency-initiative 2025-07-10T16:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/f3da07e82b19d110/alcon-s-advanced-clareon-panoptix-pro-iol-receives-canadian-approval-for-cataract-surgery 2025-07-10T16:24:19+00:00 hourly 0.9 https://trial.medpath.com/news/a0a9d640c8bfb140/nuclidium-raises-99m-series-b-to-advance-copper-based-radiopharmaceutical-platform 2025-07-10T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/464d92168957f182/arcus-biosciences-cd73-inhibitor-quemliclustat-receives-fda-orphan-drug-designation-for-pancreatic-cancer 2025-07-10T15:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/7bfc6651d53108a8/radiant-biotherapeutics-appoints-deborah-geraghty-as-president-and-ceo 2025-07-10T15:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/c269d1e7869ce49b/florida-launches-first-in-nation-newborn-genetic-screening-program-with-7-5-million-state-investment 2025-07-10T15:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/ae43160307c923a6/pds-biotech-s-novel-il-12-adc-advances-to-phase-2-stage-2-in-metastatic-colorectal-cancer 2025-07-10T12:56:30+00:00 hourly 0.9 https://trial.medpath.com/news/e116f17beb1a264d/purdue-pharma-supreme-court-petition-could-reshape-patent-obviousness-standards-for-pharmaceutical-industry 2025-07-10T12:55:59+00:00 hourly 0.9 https://trial.medpath.com/news/f207bfc19aef0976/nih-researchers-achieve-breakthrough-in-immunotherapy-for-metastatic-colon-cancer 2025-07-10T12:55:53+00:00 hourly 0.9 https://trial.medpath.com/news/01be87568c9a59bb/epitopea-strengthens-leadership-team-as-rna-based-cancer-immunotherapy-platform-advances-toward-clinical-trials 2025-07-10T12:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/6e980db7c80c97a5/crispr-gene-editing-enables-mice-to-produce-diabetes-drug-exenatide-for-sustained-weight-control 2025-07-10T12:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/07ca1c710e92531a/varda-space-industries-secures-187-million-series-c-to-advance-microgravity-drug-manufacturing 2025-07-10T12:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/9e78104cf39ad771/sanofi-advances-long-term-amlitelimab-study-for-moderate-to-severe-atopic-dermatitis 2025-07-10T12:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/debf75aa4132beb3/medidata-expands-partnership-with-university-of-sydney-to-accelerate-clinical-trial-innovation 2025-07-10T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/news/6c89d8163719bd52/tandemai-and-perpetual-medicines-merge-to-advance-ai-driven-small-molecule-and-peptide-drug-discovery 2025-07-10T12:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/cef9cdf1b84ac8ec/renasant-bio-raises-54-5m-to-develop-novel-ion-channel-therapies-for-adpkd 2025-07-10T12:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/5685e832dba7a60d/renovaro-biosciences-converts-9-7m-debt-to-equity-strengthens-ai-driven-drug-discovery-platform 2025-07-10T12:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/adb5fc10bd8964bf/biogen-s-biib080-receives-fda-fast-track-designation-for-alzheimer-s-disease-treatment 2025-07-10T10:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/42aa2dd11f4501eb/cstone-pharmaceuticals-receives-nmpa-approval-for-local-manufacturing-of-ret-inhibitor-gavreto-in-china 2025-07-10T10:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/cc55ff97b6b35704/study-reveals-critical-gaps-in-lyme-disease-follow-up-care-and-diagnostic-testing 2025-07-10T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/fa034b5bde87bba1/neurizon-receives-fda-approval-for-strategy-to-lift-clinical-hold-on-als-drug-nuz-001 2025-07-10T09:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/d35dd91b11d14bb8/genomenon-and-ucb-partner-to-advance-thymidine-kinase-2-deficiency-diagnosis-through-genomic-intelligence 2025-07-10T09:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/29639aec87125b78/biomarker-driven-precision-medicine-transforms-treatment-landscape-for-metastatic-castration-sensitive-prostate-cancer 2025-07-10T09:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/1b5c94d9865daecd/formycon-completes-enrollment-for-keytruda-biosimilar-study-skips-phase-iii-trial-with-fda-approval 2025-07-10T08:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/4b7006388a0c1fce/new-non-opioid-painkiller-journavx-faces-access-barriers-despite-fda-approval 2025-07-10T04:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/c4e980582e7036ef/metabolic-signatures-predict-immunotherapy-response-in-metastatic-melanoma-patients 2025-07-10T04:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/0d87d303f129c36e/caribou-biosciences-gains-40-over-five-days-following-fda-ind-clearance-for-cell-therapy-program 2025-07-10T04:58:42+00:00 hourly 0.9 https://trial.medpath.com/news/c068f5d3288cac68/imagion-biosystems-receives-fda-fast-track-approval-for-magsense-her2-breast-cancer-imaging-agent 2025-07-10T04:58:30+00:00 hourly 0.9 https://trial.medpath.com/news/0e7e1bcd029c01e1/galectin-therapeutics-secures-10-million-credit-line-to-advance-mash-cirrhosis-program-through-2026 2025-07-10T03:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/494434c9d316ffcb/oncology-pharmacists-expand-role-in-value-based-care-under-enhanced-oncology-model 2025-07-10T03:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/b5e41d4f37a62fa6/longevity-biotechs-attract-4-8-billion-investment-as-companies-target-aging-mechanisms-over-life-extension 2025-07-10T03:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/e877b060f6d64f33/trump-announces-100-tariff-on-branded-pharmaceuticals-starting-october-1-exempts-companies-building-us-plants 2025-07-10T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/5e3e1757d1413df7/progenra-discovers-first-in-class-pink1-activators-for-inherited-parkinson-s-disease 2025-07-10T02:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/d6c6ff0b318c0994/prokidney-secures-fda-alignment-on-accelerated-approval-pathway-for-rilparencel-in-chronic-kidney-disease 2025-07-10T00:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/11c426909c00b4e7/ultragenyx-and-mereo-biopharma-advance-setrusumab-phase-3-studies-for-osteogenesis-imperfecta-toward-year-end-analysis 2025-07-10T00:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/e9306df23ca3cc62/neumora-therapeutics-initiates-phase-1-trial-of-novel-m4-receptor-modulator-nmra-861-for-schizophrenia 2025-07-09T22:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/dc45893d7bc68bb4/benitec-biopharma-advances-bb-301-gene-therapy-trial-for-opmd-following-positive-safety-review 2025-07-09T21:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/84c3105208c9e43f/geniphys-receives-fda-510-k-clearance-for-first-in-class-self-assembling-collagen-scaffold-for-wound-care 2025-07-09T21:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/7356973fe939dc34/granules-india-recalls-33000-bottles-of-blood-pressure-medication-in-us-due-to-manufacturing-defects 2025-07-09T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/0235714b036ba3bd/israeli-scientists-develop-first-mrna-vaccine-against-bacterial-infection-targeting-plague-pathogen 2025-07-09T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/02eb5598e22b0915/fda-accepts-taiho-s-application-for-inqovi-venetoclax-combination-in-acute-myeloid-leukemia 2025-07-09T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/83fc1fc38e71493f/rhythm-pharmaceuticals-setmelanotide-shows-breakthrough-results-in-rare-hypothalamic-obesity-trial 2025-07-09T21:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/4e889339615a7c0b/ofichem-group-acquires-avivia-to-expand-complex-formulation-development-capabilities 2025-07-09T20:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/00254bb2d894b357/xaira-therapeutics-appoints-jeff-jonker-as-president-and-coo-to-scale-ai-driven-drug-discovery-platform 2025-07-09T20:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/c39a512d4fbe3c0f/australian-researchers-develop-ai-designed-protein-to-combat-antibiotic-resistant-e-coli 2025-07-09T20:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/c42fe9f2ffc4d38c/zhimeng-biopharma-s-cb03-154-receives-chinese-regulatory-approval-for-als-phase-2-3-trial 2025-07-09T20:23:04+00:00 hourly 0.9 https://trial.medpath.com/news/c1dcd2aa8d3eb22e/anthem-biosciences-positions-as-china-alternative-in-3-4-billion-ipo-amid-global-supply-chain-shift 2025-07-09T20:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/aac47de0662906bf/kolon-tissuegene-expands-tg-c-cell-gene-therapy-to-spinal-indications-with-fda-approval 2025-07-09T20:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/acd6221937acde17/beyondspring-s-plinabulin-shows-promise-in-reversing-immune-checkpoint-inhibitor-resistance-across-multiple-cancer-types 2025-07-09T19:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/5d5c6eed10886bb4/empagliflozin-demonstrates-cost-effectiveness-in-chronic-kidney-disease-treatment-empa-kidney-analysis-shows 2025-07-09T19:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/b723c80404b7c184/leo-pharma-s-tralokinumab-meets-all-endpoints-in-phase-3b-hand-atopic-dermatitis-trial 2025-07-09T18:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/930068a103a2cd13/mit-develops-implantable-device-for-automated-glucagon-delivery-to-prevent-diabetic-hypoglycemia 2025-07-09T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/518797155c29fd4f/metformin-shows-promise-in-preventing-severe-morning-sickness-in-early-studies 2025-07-09T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/ff205c5a3ef0b7d2/wearable-device-algorithm-detects-covid-19-infections-seven-days-earlier-than-symptom-based-screening 2025-07-09T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/071982bd7e4ce046/sartorius-stedim-biotech-partners-with-sensible-biotechnologies-to-scale-cell-based-mrna-manufacturing-platform 2025-07-09T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/ee4e4933c7135bbb/evoke-pharma-secures-patent-extension-for-gimoti-nasal-spray-extending-market-exclusivity-to-2036 2025-07-09T17:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/246e167b0dddceec/celularity-partners-with-fountain-life-to-deploy-stem-cell-therapies-under-new-florida-law 2025-07-09T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/d0616dbeb3a20501/neuros-medical-secures-56-million-series-d-to-commercialize-fda-approved-post-amputation-pain-treatment 2025-07-09T17:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/88964782243122ce/experimental-coq10-precursor-treatment-shows-dramatic-results-in-8-year-old-with-rare-fatal-disease 2025-07-09T16:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/ad35ce73cfda2ec1/astrazeneca-launches-primula-preg-study-to-evaluate-anifrolumab-safety-during-pregnancy-in-sle-patients 2025-07-09T16:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/6eedb4642ed21c61/novartis-secures-exclusive-option-for-sironax-s-blood-brain-barrier-platform-in-175m-deal 2025-07-09T16:29:14+00:00 hourly 0.9 https://trial.medpath.com/news/fdb0172c8506a593/kala-bio-completes-phase-2b-pced-trial-enrollment-no-fda-approved-options-exist 2025-07-09T16:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/d3400da265efaa71/piper-sandler-initiates-overweight-rating-on-inovio-pharmaceuticals-ahead-of-potential-fda-approval-for-ino-3107 2025-07-09T16:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/baf75ffef0c2deab/four-company-consortium-launches-ai-driven-drug-discovery-for-subarachnoid-hemorrhage-complications 2025-07-09T16:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/5a0adb746b81fe25/revolution-medicines-partners-with-iambic-therapeutics-in-25m-ai-driven-drug-discovery-collaboration-for-ras-addicted-cancers 2025-07-09T16:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/da8c823edcb40c8d/exactech-receives-fda-clearance-for-first-to-market-scapula-reconstruction-system-targeting-post-surgical-fractures 2025-07-09T16:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/a14e01c7b0b7ffe8/spt-labtech-and-semarion-partner-to-automate-cell-based-drug-screening-workflows 2025-07-09T16:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/db2f708c8da3a265/uk-issues-class-2-recall-for-zaditen-eye-drops-batch-due-to-potential-microbial-contamination-risk 2025-07-09T16:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/cc5f891b0d186e95/cingulate-appoints-chief-legal-officer-as-company-prepares-fda-filing-for-novel-adhd-treatment 2025-07-09T16:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/d193a6f0d441d9b6/suvoda-and-greenphire-complete-merger-to-create-integrated-clinical-trial-technology-platform 2025-07-09T16:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/1db71ec547280a7e/salarius-pharmaceuticals-seclidemstat-gains-validation-as-lsd1-inhibitor-in-new-studies-while-phase-1-2-trial-advances 2025-07-09T14:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/7a1a5385f16036ec/abl-bio-terminates-adc-platform-technology-contract-with-intussell-over-patent-concerns 2025-07-09T13:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/8f05a170c18911df/fda-approves-two-il-23-inhibitors-for-crohn-s-disease-as-gastroenterology-advances-in-2025 2025-07-09T13:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/48ab98201e884078/nature-study-validates-lixte-s-pp2a-inhibitor-lb-100-for-enhanced-cancer-immunotherapy 2025-07-09T13:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/38cd785cc25d535b/alvotech-acquires-swiss-packaging-specialist-ivers-lee-to-expand-biosimilar-manufacturing-capacity 2025-07-09T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/01b0a493ce55d8b3/hhs-quietly-advances-marburg-and-sudan-ebolavirus-vaccine-development-despite-kennedy-s-vaccine-skepticism 2025-07-09T13:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/46d0f88c1eb2a59c/mattel-launches-first-type-1-diabetes-barbie-doll-with-medical-device-accessories 2025-07-09T13:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/e45b184296e1f353/phesi-ceo-warns-of-impending-phase-3-trial-failures-due-to-site-oversaturation-and-complex-design 2025-07-09T12:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/85378c3021a23542/centivax-secures-45-million-series-a-to-advance-universal-flu-vaccine-into-phase-i-clinical-trial 2025-07-09T08:55:48+00:00 hourly 0.9 https://trial.medpath.com/news/25ed0c037089f9c3/lupin-secures-50-million-licensing-deal-with-zentiva-for-global-certolizumab-pegol-biosimilar-rollout 2025-07-09T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/news/15ed7304581ffd35/dri-scientists-achieve-diabetes-reversal-using-small-peptide-thr-123-in-preclinical-models 2025-07-09T08:54:55+00:00 hourly 0.9 https://trial.medpath.com/news/988947f75a7c5e12/johnson-johnson-seeks-european-approval-to-expand-akeega-for-metastatic-prostate-cancer-with-genetic-alterations 2025-07-09T08:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/22b85dcc9a4aa0a7/biomed-x-and-servier-launch-first-european-xseed-labs-to-advance-ai-driven-bispecific-antibody-design 2025-07-09T08:18:35+00:00 hourly 0.9 https://trial.medpath.com/news/84c22f7b6596ab24/merck-announces-10-billion-acquisition-of-verona-pharma-to-expand-copd-treatment-portfolio 2025-07-09T08:18:08+00:00 hourly 0.9 https://trial.medpath.com/news/7dde9408e7dd12e1/nurexone-s-exopten-achieves-100-motor-function-recovery-in-spinal-cord-injury-preclinical-study 2025-07-09T07:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/6d8b0d771afc1c49/aktiia-s-hilo-band-becomes-first-fda-cleared-cuffless-blood-pressure-monitor-for-over-the-counter-use 2025-07-09T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/a5e38edabad49f40/two-new-tuberculosis-drugs-show-superior-safety-profile-over-linezolid-in-phase-2b-trials 2025-07-09T05:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/4220eca6b703c187/aptar-develops-dual-active-material-science-technology-for-glp-1-drug-protection 2025-07-09T04:20:27+00:00 hourly 0.9 https://trial.medpath.com/news/087a0e06610c5f18/bionxt-solutions-advances-targeted-chemotherapy-delivery-platform-to-enhance-precision-oncology 2025-07-09T04:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/92db9e36fc00c9b8/molecular-testing-and-circulating-tumor-dna-advances-set-to-transform-gist-management 2025-07-09T03:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/46448a7ea6393981/large-scale-meta-analysis-confirms-strong-association-between-alopecia-areata-and-multiple-immune-mediated-disorders 2025-07-09T03:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/73b4bba71d299749/medical-organizations-sue-rfk-jr-over-unlawful-covid-19-vaccine-policy-changes 2025-07-09T03:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/41d08f5899e944fd/johnson-johnson-launches-varipulsetm-pulsed-field-ablation-platform-across-asia-pacific-for-atrial-fibrillation-treatment 2025-07-09T01:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/fb5e60f6556f30db/cresset-acquires-molab-ai-to-enhance-ai-driven-drug-discovery-platform 2025-07-09T01:20:16+00:00 hourly 0.9 https://trial.medpath.com/news/314d0008434608ad/j-j-wins-federal-circuit-appeal-preserves-invega-sustenna-patent-protection-until-2031 2025-07-09T01:19:52+00:00 hourly 0.9